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Abstract
Molecular imaging probes allow for the non-invasive diagnosis of many diseases through
the use of a targeting entity for site specific delivery, as well as a signal for external
visualization of probe accumulation in the body. This thesis will focus on the
development of new approaches to synthesize targeting peptides and chelators for
radionuclide incorporation towards the design of novel molecular imaging probes.
Histidine is a tridentate chelator that can be attached in a pendant fashion to a
biomolecule in order to coordinate technetium-99m. Once coordinated, it forms a neutral
complex that is capable of forming diastereomers with inverted stereochemistry at the
alpha amine of the histidine. This is demonstrated through the synthesis and
characterization, with LC-MS and 2D NMR spectroscopy, of four different histidine
chelators that upon rhenium coordination form two products.
Copper-catalyzed azide-alkyne cycloaddition, or “click”, reactions form a 1,2,3-triazole
that can be used to cyclize peptides, as well as coordinate [99mTc/Re(CO)3]+. Clickable
peptides can be developed combining these two concepts, such that a chelation site is
created as a result of peptide cyclization in order to facilitate incorporation of
[99mTc/Re(CO)3]+ within the peptide. In order to do this, azide and alkyne modified
amino acids can be incorporated into peptide sequences and reacted to form a triazole
containing chelation sphere while simultaneously cyclizing the peptide.
Simultaneous peptide cyclization and [99mTc/Re(CO)3]+ coordination was also performed
with pentapeptides of the form Ac-HAAAH-OH. This was done in a [2+1] fashion using
the imidazole of the N-terminal histidine and the imidazole and carboxylic acid of the Cii

terminal histidine. Peptide coordination was verified through LC-MS, while
computational studies as well as 2D and VT NMR spectroscopy allowed for the
determination of the mode of coordination.
Finally, water soluble gold nanoparticles were conjugated with bombesin, a peptide
known to target gastrin-releasing peptide receptors that are overexpressed in prostate
cancer. This was done through the use of click chemistry to attach an azide modified
bombesin to alkyne modified gold nanoparticles. Through transmission electron
microscopy studies, these targeted nanoparticles showed specific uptake in prostate
cancer cells, demonstrating their utility for targeting prostate cancer for both diagnostic
and therapeutic purposes.

Keywords
Radiopharmaceuticals, Molecular imaging probes, Rhenium, Technetium-99m, Click
chemistry, Peptide cyclization, Histidine, Gold nanoparticles
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Chapter 1

1

Introduction

1.1 Molecular Imaging
In the last few decades, molecular imaging has become an integral component in the noninvasive diagnosis of many diseases, allowing for the in vivo observation of biochemical
processes at the molecular and cellular level.1 This technique uses biomarkers to
visualize, characterize and measure biological processes within a living system. An
image is obtained through the external detection of the biomarker, which has been
injected into a patient, through the use of sophisticated diagnostic imaging equipment.
There are a wide variety of biomarkers available for imaging many different targets and
pathways in vivo, based on their chemical and biological properties.
In this way, molecular imaging can be used to non-invasively image tumours, and other
diseases, allowing for pre-symptomatic disease detection. Not only is it useful for early
diagnosis, but it can also be used to estimate disease staging, allowing for more a more
personalized treatment approach. Molecular imaging can also be applied to track the
progression of response to determine whether the choice is effective, or if a new approach
needs to be followed. In order to accomplish this, a strategy must be developed that can
differentiate between diseased and normal tissues using a molecular imaging probe.

1.2 Molecular Imaging Probes
In the past, perfusion agents were common; however, these have a very low targeting
efficiency.2 Therefore, recent advances have been made in the area of targeted molecular
imaging probes. These probes are developed to target biomolecules that are

2

overexpressed on malignant tissues yet absent, or present in much lower concentration,
on non-malignant tissues. Imaging probes must be designed so that they can be used to
target the desired receptor and allow for external detection. These probes are comprised
of two different components (Figure 1.1); a targeting entity provides site specific delivery
of the probe to the malignant tissue, and a labelling moiety permits external detection of
the target. If designed properly, an imaging probe can target a receptor that is specifically
over-expressed on the malignant tissue and accumulate in high target to non-target ratio,
which can then be detected externally due to the presence of the label.

Targeting

Label

Entity

Figure 1.1: Schematic of a molecular imaging probe

1.2.1 Targeting Entity
The targeting entity component of an imaging probe must selectively bind to the tissue of
interest in much higher concentration in the diseased state than the surrounding healthy
tissue, in order to be effective. If this is the case, a high target to non-target ratio will be
achieved, increasing the contrast in the image, as well as the precision and accuracy in
diagnoses.3 The targeting entity can vary depending on the desired target, with the most
common being small molecules, peptides and monoclonal antibodies. Peptides have
many desirable characteristics required for use as targeting entities.4 As such, peptidebased probes can be designed for many biological targets and tend to have high uptake in
target tissue while still maintaining rapid clearance from the blood and non-target tissue.
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They also tend to have minimal side effects and low toxicity.5 In addition, they are easily
synthesized and modified to enhance pharmacokinetic properties, and can be easily
labelled with a wide range of isotopes, including radiometals, and optical agents,
allowing for use with a variety of imaging modalities. Peptides also have a high enough
molecular weight to allow for the addition of metal chelators, but still have low enough
molecular weight for rapid clearance. In some cancers, endogenous peptide receptors
tend to be over-expressed, making peptides ideal targeting molecules.5-7
However, peptides are not without their disadvantages. The main concern with peptides is
their low biological half-life, which is often in the range of minutes as they quickly
undergo enzymatic degradation in vivo. Linear peptides also have a very flexible
backbone resulting in interactions with multiple receptors, decreasing their selectivity.8
As well, the addition of the imaging entity often decreases the binding affinity of the
peptide for the receptor. Therefore, optimization is required before peptides can be used
as targeting entities.
Peptidomimetics are molecules designed to mimic peptides in vivo. This generally entails
altering the peptide backbone or incorporation of unnatural amino acids into the peptide
sequence. This can decrease the rate of enzymatic degradation, greatly increasing the in
vivo stability of the probes.9,

10

Cyclic peptides are also useful for this purpose as

cyclization restricts the flexibility of the peptide backbone, minimizing receptor binding
promiscuity, and occasionally enhancing the binding affinity of the probe. Octreotide, for
example, is a synthetic eight amino acid peptidomimetic of somatostatin, a naturally
occurring hormone that has a cyclic structure. The linear version of octreotide binds to
the somatostatin receptor with a much lower affinity than the cyclic version, suggesting
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that a specific conformation is required to achieve higher binding affinities.11
Somatostatin has an in vivo half-life of only two to three minutes, whereas octreotide has
a half-life of approximately one to two hours. This is most likely due to the substitution
of natural L-tryptophan for unnatural D-tryptophan, allowing it to withstand enzymatic
degradation.12

1.2.1.1

Solid-Phase Peptide Synthesis

Peptides can be synthesized either in solution or, more commonly, on a solid support.
Solution phase peptide synthesis can be problematic, as dimerization and formation of
other unwanted by-products requires purification steps after the addition of every amino
acid. In the 1960s, solid-phase peptide synthesis (SPPS) was introduced by Merrifield.13
In SPPS the peptide is attached to a solid support, providing a pseudo-dilution effect,
making the formation of dimers much less likely. As well, an excess of reagents can be
used in order to drive the reaction to completion. This is possible as all excess reagents
and any by-products are dissolved in the solvent and, thus, can be washed away while
leaving the peptide chain on the resin, eliminating the need for tedious purification of
intermediates. SPPS can also be performed either manually, or by an automated peptide
synthesizer, making synthesis much more convenient.
To synthesize a peptide by SPPS, an amino acid is attached to an insoluble solid support
resin bead, and the peptide is extended from the C-terminus to N-terminus. The first
amino acid is loaded onto one of the functionalized chains attached to the polymer bead,
and subsequent amino acids are coupled to form a peptide chain. The progress of the
synthesis can be checked by cleaving small amounts of peptide from the resin and
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checking by LC-MS. After the desired length is reached, the chain can then be cleaved
from the resin to yield the linear peptide.
A

common

method

to

synthesize

peptides

by

SPPS

is

the

Fmoc

(fluorenylmethoxycarbonyl) strategy. This strategy uses orthogonal protecting groups in
order to keep the amino acid side-chains protected, while removing the N-terminal
protecting group to attach the next amino acid to the chain. The peptide is generally
attached to an acid sensitive resin, the amine group on the amino acid is protected by a
base labile Fmoc group, and the side-chains are protected by acid labile protecting
groups. In this way the Fmoc can be removed while leaving the side-chains protected,
and the peptide on the resin. The peptide can then be removed from the resin by treatment
with acid while simultaneously removing the side-chain protecting groups.
The resin bead is an insoluble polymer support and can contain varying functional
groups. The choice of resin depends on the functional group desired on the C-terminus of
the peptide once it is cleaved. For example, a Rink amide resin is functionalized with a
free amine that attaches to the carboxyl group of the first amino acid, and forms an amide
when it is cleaved with acid as opposed to a carboxylic acid as is seen when using Wang
resin.
In SPPS, a protected amino acid is loaded onto an insoluble resin through standard
coupling procedures to form a peptide bond. The N-terminal protecting group is then
removed; in the case of Fmoc, piperidine is used. This is then followed by coupling of the
next protected amino acid. This cycle is continued until the desired peptide length is
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reached, at which point, the peptide can be cleaved from the resin and the protecting
groups removed to give the desired peptide (Figure 1.2).

Figure 1.2: Fmoc-based solid-phase peptide synthesis cycle14

1.2.2 Imaging Entity
The imaging entity of a molecular imaging probe allows for the external detection of the
localization of the probe. There are many types of imaging entities available with the
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choice depending on the intended application as well as the desired imaging modality.
Optical imaging requires addition of a fluorophore or bioluminescent enzyme to the
targeting entity, and can be used for in vitro cell studies or in vivo applications.7 These
include fluorescent probes that emit photons with 300-600 nm wavelengths. This
wavelength cannot penetrate tissue without attenuation, and thus is generally used for in
vitro cell studies.15 Near infrared (NIR) dyes can also be used with wavelengths ranging
between 650-900 nm. These wavelengths are able to penetrate tissue and are suitable for
in vivo applications.15 Many imaging modalities in nuclear medicine require the use of a
radionuclide as an imaging entity for use in radiopharmaceuticals. The development and
use of radiopharmaceuticals will be discussed in further detail in the following section.

1.3 Radiopharmaceuticals
A radiopharmaceutical is a perfusion agent or molecular imaging probe that is composed
of a targeting entity labelled with a radionuclide for use in non-invasive diagnosis and
treatment of many diseases, including cancer. In order to design a molecular imaging
probe, a biologically active entity must be chosen based on its ability to accumulate at a
specified target with a high target to non-target ratio. It is administered in trace quantities,
as very little radiation is required; as a result it has no pharmacologic effect on the
patient.16 Next, a suitable radionuclide must be attached to the targeting entity. The
choice of radionuclide determines whether the radiopharmaceutical will be used for
diagnostic or therapeutic purposes, however, approximately 95% of radiopharmaceuticals
are used for diagnosis.17
For diagnosis, the radionuclide must emit a gamma-ray between 50 and 600 keV to allow
for external detection.3 It must also have a short half-life so the radiation dose to the
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patient remains low; ideally, only long enough to allow for radiosynthesis, purification,
injection, biodistribution and imaging. Availability, ease of production and cost also play
a major role in choice of a radionuclide. The radionuclide must also quickly and easily be
incorporated into the biomolecule of choice through direct displacement and addition of a
prosthetic group, or the use of a chelator. After addition of the radionuclide, the final
radiopharmaceutical should still retain a high target to non-target ratio in order to be an
effective diagnostic probe.3, 4
Alpha (α) and beta (β-) emitting radionuclides cause much more damage to surrounding
tissue than γ–rays and thus should not be used for diagnostic purposes. While tissue is
transparent to γ-rays, it is not transparent to α and β- particles which have limited
penetration depths of only a few µm, therefore they do not offer any diagnostic benefit.
They can, however, be used for therapeutic purposes as they cause radiation damage to
the targeted tissues.17

1.4 Technetium-99m
Technetium-99m (99mTc) is a manufactured element discovered by Perrier and Segré in
1937.18 In just over 75 years it has become the most common radionuclide used in
diagnostic nuclear medicine, used in more than 80% of radiopharmaceuticals.19 It is an
ideal radionuclide as it has a half-life of six hours which is long enough for labelling
procedures as well as obtaining an image, but short enough that the dose of radiation to
the patient remains very low.20 As well, the gamma emission from the decay of

99m

Tc is

140 keV. This is energetic enough to pass through tissues, but not too high energy so as
to give the patient a high dose of radiation. The decay occurs by release of a γ-ray
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through an isomeric transition to technetium-99, which has a radioactive half-life of 2.12
times 105 years (Figure 1.3).

Figure 1.3: Decay scheme of 99Mo to 99Ru
In the 1950s, researchers at the Brookhaven National Laboratory developed the
molybdenum-99/technetium-99m generator,21 which is currently how the majority of
technetium-99m is obtained. The generators produce the 99mTc from 99Mo at the location
at which it is needed, thus decreasing the number of half lives the 99mTc undergoes before
it is used in synthesis. The molybdenum-99 is produced in a nuclear reactor by the fission
of uranium-235, and once purified can be loaded onto an alumina anion exchange
column. The 99Mo has a half-life of 66 hours, allowing it to decay to
99

99m

Tc (87.5%) and

Tc (12.5%) through β- decay while still on the column.3, 22 The adsorbed 99mTc can then

be eluted from the column using saline solution as sodium pertechnetate (Na[99mTcO4]-)
and collected in an evacuated sterilized vial (Figure 1.4). The majority of the

99m

Tc
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produced occurs in the first three parent half lives, therefore, the generator needs to be
replaced approximately every week. Even with frequent replacement, the generator
system allows the technetium-99m to be more readily available, and thus less expensive
than many other diagnostically relevant radionuclides.23

Figure 1.4: Schematic of a 99Mo/99mTc generator24

1.5 Rhenium Analogues
As technetium-99m is radioactive, only nanogram quantities can be used, making the use
of standard spectroscopic methods for characterization impractical. A solution to this
problem is to synthesize and characterize the desired compounds using a nonradioactive
analogue that possesses the same properties as

99m

Tc. This allows for larger quantities to

be synthesized and characterized, before moving on to radioactive versions.
Rhenium is typically used in the place of technetium during the synthetic stages as it has
similar chemical properties. It is in the same group as technetium, located one row below
in the periodic table and exists as two stable isotopes,

185

Re (37.4%) and

187

Re (62.6%).

The chemistry of technetium and rhenium is comparable, not only having the same size
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and shape, but also formal charge and lipophilicity.6, 25 This makes the rhenium analogue
nearly identical to the technetium-99m compound, allowing for larger quantities of the
complex to be synthesized and characterized, prior to radiolabelling with technetium99m, thus minimizing exposure to radioactive products. Rhenium can therefore be used
as a non-radioactive substitute for technetium when designing compounds for use as
imaging agents.

1.6 Technetium-99m Radiopharmaceuticals
Technetium exists in various oxidation states from 1- to 7+; however, no clinically
relevant compounds have been prepared using the 0, 2+ or 6+ oxidation states.17 A
variety of clinically relevant compounds have been formed using technetium in the 3+,
4+ and 7+ oxidation states, but the focus of research was previously on Tc(V).26 This
oxidation state was used with the [Tc=O]3+ and [O=Tc=O]+ cores to form square
pyramidal or octahedral complexes, respectively, with various bi- or tetradentate ligand
sets.27
More recently, the Tc(I) oxidation state has been developed for use in
radiopharmaceuticals and is found predominantly in octahedrally coordinated

99m

Tc/Re

tricarbonyls.28-33 This has become the most promising technetium core as they are
chemically inert and have a nearly spherical shape, making them very compact. The
carbonyl ligands orient themselves in a facial arrangement, causing the trans ligands to
become very labile, allowing for straightforward substitution by the chelator. These are
generally used with tridentate chelators (Figure 1.5) as they tend to form a more stable
complex that is protected against ligand attack or re-oxidation. As well, they tend to react
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very fast, making them ideal for radiolabelling as the time required for synthesis can be
decreased.19, 23

Figure 1.5: Schematic of a 99mTc(I)/Re(I) tricarbonyl core with a tridentate chelator34
The [99mTc(CO)3]+ precursor is easily synthesized as the tri-aqua complex in quantitative
yields and excellent radiochemical purity by adding pertechnetate ([99mTcO4]-) eluted
from a generator to commercially available Isolink kits.35, 36 These kits contain sodium
tartrate, sodium tetraborate, sodium carbonate, and disodium boranocarbonate, which
reduces the technetium in the pertechnetate from the +7 oxidation state to +1, and also
acts as a carbonyl source.19,

23

This provides a quick synthetic procedure for the

precursor, allowing for decreased synthesis times, and thus fewer elapsed half-lives. This
Isolink kit, however, cannot be used to prepare [Re(CO)3(H2O)3]+ as rhenium is slower to
react and harder to reduce than technetium.23
The [99mTc(CO)3]+ core requires a ligand chelation system for biomolecule incorporation.
Technetium is a group 7 transition metal, existing as d6 in its 1+ oxidation state. It has a
low charge to ionic radius ratio, making it a soft metal. Although this means that it has a
preference for soft π-acceptors, it can also bind hard σ-donors. This is due to the
chemistry of the CO ligands. If there is an increase in CO π-backbonding, an electron
deficient metal centre is produced, allowing for coordination of hard σ-donors. If there is
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a stronger σ-donation from the CO to the metal, an increase in electron density on the
metal occurs, resulting in coordination of soft π-acceptors. This allows the [99mTc(CO)3]+
core to coordinate to a variety of donor and acceptor ligands.37
The water molecules of the [99mTc(CO)3(H2O)3]+ core are facially coordinated and
experience a strong trans influence from the facially coordinated carbonyl ligands. This
effect causes the water molecules to be extremely labile, whereas the carbonyl ligands
remain stable and cannot be substituted by incoming ligands.23 This allows for easy
substitution of the water molecules by chelators. Coordinating groups such as imidazoles,
pyridines, pyrazoles, amides, carboxylic acids, thioethers, thiols and phosphines have
been shown to coordinate well with the [99mTc(CO)3]+ core.37
Technetium-99m radiopharmaceuticals are generally composed of a biomolecule for
targeting, the radiometal for external detection, and a chelator to attach the metal to the
biomolecule. The metal complex can be added to a targeting peptide through two
different approaches; pendant or integrated design (Figure 1.6). Pendant design is the
classic approach where a bifunctional chelator is attached in a pendant fashion to the
peptide through functionalization of either the side chain of an amino acid, such as lysine,
or the carboxy or amine terminus of the peptide. A bifunctional chelator allows for
attachment of the chelator to the biological entity while still allowing for coordination to
the technetium core, placing the metal complex away from the biologically active site.
The drawback to this approach is that adding a bulky chelator to the outside of the
peptide is likely to affect the binding of the original peptide to the receptor. Therefore,
further optimization with the attached metal complex must be performed.
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Figure 1.6: Schematic of pendant and integrated technetium-99m peptide-based
radiopharmaceutical designs
An alternative approach is to form an integrated radiopharmaceutical where the metal is
incorporated into the backbone of the peptide. This “hides” the metal in the molecule,
minimizing interference with binding of the biomolecule to the receptor, and in some
cases is an integral component in locking the peptide in its active form, making the metal
imperative for biological activity. Integration can be achieved using cyclic peptides, or
turn mimics, where the chelator can be incorporated into the turn region of the peptide, or
a chelator can be formed as a result of peptide cyclization. This eliminates the need for
addition of a bulky chelator, makes the complex more compact and decreases the
molecular weight of the probe. The smaller size of integrated technetium complexes
make them less likely to interfere with the binding of the probe to the target.37 As well,
lower molecular weight compounds are preferred as they more readily penetrate tumours
and have faster clearance leading to higher tumour-to-background ratios.38
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Technetium-based radiopharmaceuticals have passed through three distinct generations,
with the first two of these generations achieving clinical applications.39 The first
generation consists of perfusion agents, which do not contain a targeting entity. Due to
their convenient synthesis and low cost, these first generation agents account for the
majority of clinically used radiopharmaceuticals. Some of the first technetium-99m based
radiopharmaceuticals were

99m

Tc-gluconates and

99m

Tc-glucoheptonates used for renal

clearance studies.40 While clinically relevant examples include: Tc-MIBI (Cardiolite®)
for myocardial imaging;41 Tc-HMPAO (Ceretec®) for cerebral blood flow imaging;42 and
Tc-MAG3 (Technescan®) for renal clearance studies.43
Second generation technetium-based radiopharmaceuticals are target-specific, containing
a targeting entity and a bifunctional chelator for technetium-99m.

99m

Tc labeled tropane

systems target brain receptors and have been tested for diseases such as Alzheimer’s,
Parkinson disease and schizophrenia.44-46 A clinically tested example is 99mTc-TRODAT1 which targets the dopamine receptor with high affinity.47
The third generation models follow an integrated design, where the radiometal is
essential for binding. These include rhenium and technetium labelled steroid analogues,
first introduced by the Katzenellenbogen group.48-50 Although no third generation
radiopharmaceuticals have reached the clinic, prostate specific membrane antigen
(PSMA) targeting compounds using single amino acid chelate (SAAC) systems51, 52 for
metal coordination are currently in Phase II clinical trials.
Peptide-based technetium-99m radiopharmaceuticals fall into the second and third
generation models as they possess a targeting peptide. Some of the most common
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peptides used in targeted technetium-99m based radiopharmaceuticals are: RGD
analogues that target the αvβ3 integrin for imaging of angiogenesis;53-55 bombesin
analogues targeting the gastrin-releasing peptide receptor;38, 56-59 somatostatin analogues
targeting

somatostatin-receptor-positive

neuroendocrine tumour imaging;63,

64

tumours;60-62

neurotensin

analogues

for

and neuropeptide analogues for imaging a wide

range of tumours.65

1.7 Emission and Computed Tomography
Emission tomography is a form of functional medical imaging that measures γ–ray
emission in order to form a three-dimensional image of physiological processes in vivo.
There are two forms of emission tomography used for molecular imaging; positron
emission tomography (PET) and single photon emission computed tomography (SPECT).
Although their principles are very similar, their instrumentation, radiochemistry and
emission are quite different.
In order to obtain an image, a radiotracer is injected into the patient and allowed to
circulate through the body and accumulate in the tissue of interest. γ-rays are then emitted
from the source and detected using a gamma camera. The gamma camera contains
sodium iodide crystals doped with small amounts of thallium that emit a light photon
once a γ-ray is detected. This light photon then strikes a photomultiplier tube causing a
transformation to an electronic signal which is amplified by a preamplifier. This signal is
converted to a digital signal to produce an image.17 The gamma camera is also equipped
with a lead collimator which limits the field of view to decrease detection of scattered
radiation from γ-rays emitted from areas of the body other than the tissue of interest, thus
increasing the sensitivity of the instrument.3
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Emission tomography can further be combined with computed tomography (CT) which
uses an X-ray source and a parallel detector that rotate around the patient to acquire
several two-dimensional X-rays from various angles to obtain three-dimensional
anatomical images. Once fused, the objects seen in the functional SPECT or PET image
can be given a relative position in the body using the anatomical CT image.

1.8 Positron Emission Tomography
Positron emission tomography (PET) is a highly sensitive, non-invasive form of
molecular imaging that can construct a three-dimensional image through detection of
injected tracers labelled with positron emitting radionuclides. These positron emitting
radionuclides are generally short lived, with half-lives ranging from 10 minutes to 13
hours, although there are examples of longer lived PET radionnuclides such as Zr-89 with
an 80 hour half-life. As well, they can be either generator or cyclotron produced. In PET
imaging, postitron emission is indirectly measured through the production of γ-rays. A
positron emitting radionuclide such as fluorine-18 decays to a neutron, releasing a
positron and a neutrino in the process. Once the positron is emitted it travels a short
distance (< 2 mm) where it annihilates with an electron from the surrounding tissue. This
annihilation event causes two 511 keV photons to be emmitted at a 180o angle.3, 66 These
photons are then detected by a PET scanner (Figure 1.7a) containing a circular detector
that can recreate the image based on the line of coincidence, displaying the
biodistribution and accumulation of the tracer in the body (Figure 1.7b).
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a)

b)

Figure 1.7: a) PET scanner,67 and b) schematic of a PET scanner and positron
annihilation68
As stated above, a PET image can be combined with a CT image in order to combine
both a functional and anatomical image. This also helps to increase the relatively poor
resolution of PET imaging with the high resolution of CT imaging.3 These images can be
taken consecutively; however, there is error in even fine movements of the patient over
time from breathing or small movements. A PET/CT scanner has recently been
developed that can obtain both a PET and CT image simultaneously, eliminating error
from patient movement. In this way, the PET and CT images can be superposed to obtain
an image giving a much better idea of the relative placement of the tumour in the body
than a PET image alone. Figure 1.8 shows examples of a CT, PET and fused PET/CT
images of a bone scan of a mouse. The CT image gives an anatomical image of the
mouse whereas the PET image shows the accumulation of the probe in the mouse. Once
fused, a more accurate representation of the location of the accumulation can be seen
with higher accumulation of the radiotracer represented by the brighter red areas,
showing the bone metastases.
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Figure 1.8: CT, PET and fused PET/CT images of a 18F sodium fluoride bone scan of a
mouse69

1.9 Single Photon Emission Computed Tomography
Single photon emission computed tomography (SPECT) is the most widely used imaging
modality in diagnostic nuclear medicine. It uses gamma-emitting radionuclides, such as
technetium-99m, that have emission energies between 100 and 300 keV as they are
energetic enough to pass through the body and be externally detected, but are not high
enough energy to cause unnecessary harm to the patient.3 As is the case with PET
isotopes, SPECT isotopes can be obtained from a cyclotron or a generator; however, they
generally have much longer half-lives, ranging from 6 hours to 2.8 days, allowing for
transportation of the isotopes from off-site cyclotron facilities, as well as more time for
synthesis, administration and accumulation of the tracer prior to imaging.
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SPECT imaging is very similar to PET imaging in that it uses γ-rays to construct threedimensional functional images of radiotracer accumulation in the body. However, the
radionuclides used are gamma-emitters; therefore, γ-ray emission is detected directly. As
this is not a coincidence event, the photons are unidirectional. Therefore, a SPECT
scanner (Figure 1.9a) has a gamma camera that rotates 180o or 360o around the patient,
whereas the detector in a PET scanner remains stationary. The detector must rotate as γrays are emitted from the tumour from all angles, and in order to determine the location
of the tracer accumulation and obtain a three-dimensional image, the detector must
acquire multiple two-dimensional images at various angles around the patient (Figure
1.9b).
The unidirectional nature of the photons makes it much harder to determine the location
of the γ-emission, making SPECT a lower resolution and less sensitive technique when
compared to PET. However, SPECT is a much more cost effective method of imaging
than PET as the majority of SPECT isotopes are generator produced and have much
longer half-lives, making SPECT much more accessible than PET.

a)

b)

Figure 1.9: a) SPECT scanner,70 and b) schematic of a SPECT scanner68
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As with PET, SPECT can also be combined with CT in order to give a higher resolution
combined functional and anatomical image. Figure 1.10 shows the CT, SPECT and
SPECT/CT images of a

99m

Tc-MDP (methylene diphosphonate) bone scan of a mouse.

The CT image gives an anatomical reference for the SPECT image, which shows the
uptake of the radiotracer in the mouse, with the brighter areas showing higher uptake in
the bone metastases. The fused SPECT/CT image gives a better indication of the location
of the tracer uptake, providing a higher resolution image.

Figure 1.10: CT, SPECT and fused SPECT/CT images of a
mouse71

99m

Tc-MDP bone scan of a
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1.10

Click Chemistry

Click chemistry describes a variety of reactions that join small units together through
heteroatoms quickly and reliably. The term “click chemistry” was first used by K. Barry
Sharpless in 2001.72 There are many stipulations for reactions to be considered “click”
reactions; these include being modular, wide in scope, high yielding, stereospecific and
generating inoffensive byproducts. The reaction must also be simple, insensitive to
oxygen and water, requiring only readily available starting materials, benign or easily
removed solvents, and the product must be easily isolated.72 These conditions would
allow for easy and reproducible reactions for joining two or more units together for a
variety of purposes. These click reactions generally fall into one of four categories;
cycloaddition reactions, nucleophilic ring-opening reactions, non-aldol carbonyl
chemistry and addition to carbon-carbon multiple bonds.73
The most common reaction that is associated with “click chemistry” is the azide-alkyne
cycloaddition. This 1,3-dipolar cycloaddition reaction was first discovered by Rolf
Huisgen in 196174 and was described by Sharpless as being the “cream of the crop” of
click reactions.72 It irreversibly combines an internal, or more commonly a terminal
alkyne and terminal azide to form both the 1,4- and 1,5-regioisomers of the 1,2,3triazole, and was traditionally performed using high temperatures and long reaction times
(Figure 1.11).

Figure 1.11: Schematic of the Huisgen azide-alkyne cycloaddition
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1.10.1

Copper-Catalyzed Azide-Alkyne Cycloaddition

In 2001, forty years after its initial discovery, it was discovered that a copper(I) catalyst
could be used to preferentially form the 1,4- regioisomer much (up to 107 times) faster
and under much milder conditions.75 This was further improved independently by both
the Meldal and Sharpless groups in 2002.76, 77 This regioselective reaction using a copper
catalyst has become known as the copper-catalyzed azide-alkyne cycloaddition (CuAAC)
and is generally the reaction that is referred to as “click chemistry”.
As opposed to the thermal reaction introduced by Huisgen, which can take up to several
days at very high temperatures, the copper catalyzed version can go to completion in a
matter of hours at room temperature. A copper(I) catalyst, such as a copper halide, is
required for this reaction, however it is often oxidized to the Cu(II) salt and is thus
useless for the reaction. Alternatively, an in situ reduction of Cu(II) salts, such as
CuSO4.5H2O, can be performed using sodium ascorbate. This can be done using as little
as 0.1 eq of the Cu(II) salt and 0.2 eq sodium ascorbate. This way the sodium ascorbate
can prevent the re-oxidation of Cu(I) to Cu(II). This reaction can also be done in aqueous
solutions, allowing for the use of a benign solvent as stated in the requirements for a click
reaction.
The CuAAC reaction is chemoselective, as alkynes and azides are relatively inert in the
absence of proper catalysts or conditions.78 Azides have incredible stability towards
water, oxygen and most organic synthesis conditions.79, 80 Both alkynes and azides are
very unreactive to general solid-phase peptide synthesis reaction conditions; they can also
be incorporated into peptides without the concern of reacting with amino acid side chains,
even when unprotected. Both alkynes and azides can be inserted into the peptide early in
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the sequence and remain invisible throughout the synthesis.77 The conditions for the click
reaction are tolerated by many functional groups, allowing for an unprotected peptide to
be clicked in solution if desired; however, it can also be performed on solid support as the
reaction conditions have been shown to be compatible with solid-phase peptide synthesis,
all amino acids and their protecting groups.76 This reaction is also very high yielding and
extremely robust, tolerating many reaction conditions that are generally of concern. It
does not require inert atmospheric conditions, and can be performed in a variety of
solvents including aqueous alcohols, as well as pure water. It also proceeds at pH values
ranging from 4 to 12.77
This robustness has led to the CuAAC finding much versatility in chemistry and
biochemistry. It has found utility in many areas such as bioconjugation, dendrimer
synthesis, combinatorial drug discovery, and peptidomimetics.81 The 1,4-disubstituted
1,2,3-triazole formed has been found to be a peptide bond isostere, mimicking the
placement and electronic properties of the peptide bond (Figure 1.12).82, 83 It was found
through triazole scans of a biologically relevant peptide that the binding affinity of the
peptide for the target remained approximately the same and even displayed enhanced
stability compared to the natural ligand.84 Unlike peptide bonds, triazoles are not prone to
hydrolysis, enzymatic degradation, or oxidation and reduction, making the azide-alkyne
cycloaddition a very attractive method of functionalizing peptides, especially for in vivo
purposes.

25

Figure 1.12: Schematic showing similarities between peptide bonds and 1, 4disubstituted 1,2,3-triazoles (adapted from reference 82)

1.10.2

Strain-Promoted Azide-Alkyne Cycloaddition

A major issue with the CuAAC is the fact that copper is cytotoxic;85 therefore, its utility
for biological studies is limited. For this reason, the Bertozzi group developed the strainpromoted [3+2] azide-alkyne cycloaddition (SPAAC) in 2004.86 This reaction has
recently become quite popular as its lack of a copper catalyst makes it bioorthogonal and
much more practical for in vivo studies. The “catalyst” for this reaction is the strain of the
cyclic alkyne, generally a cyclooctyne as it is the smallest stable cycloalkyne. It goes to
completion under physiological conditions in the absence of any other reagent or catalyst,
and can be used to selectively modify biomolecules and living cells without any apparent
physiological harm.86 For this reason, SPAAC is becoming more widely used for
biological applications than its copper catalyzed counterpart (Figure 1.13).

Figure 1.13: Copper-catalyzed versus strain-promoted azide-alkyne cycloadditions
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The most exciting use of this reaction is the in vivo imaging of dynamic biological
processes through “pretargeting”. This is accomplished by first targeting a receptor with
either an alkyne or azide modified entity, such as a peptide or antibody. Once allowed to
circulate and uptake is achieved, a fluorescently or radiolabelled alkyne or azide is
injected and allowed to react in vivo.87 This allows for the targeting entity to react with
the receptor fully, and for the unreacted to be properly excreted from the body, increasing
the target tissue to background ratio, resulting in high quality images of dynamic
biological processes.

1.11

Gold Nanoparticles for Diagnosis and Therapy

Nanoparticles have recently been investigated for their use in cancer targeting. An ideal
nanoparticle for this purpose is the gold nanoparticle (AuNP), as they are the most stable
metal nanoparticles, they display low toxicity, are biocompatible and their surfaces are
easily functionalized.88-92 They also tend to be taken up in tumour cells due to the
enhanced permeability and retention (EPR) effect they possess, with nanoparticles less
than 100 nm having the ability to accumulate in malignant tissues.93 This is due to blood
vessel formation that occurs in response to tumours through angiogenesis, which tends to
form irregular and more permeable vessels, allowing for “passive targeting” of the
AuNPs; this uptake mechanism however, is non-specific. Specific uptake can be
accomplished through the addition of a targeting entity, such as a peptide, antibody or
small molecule to the nanoparticle. Specific uptake is more desirable, as it allows for
accumulation of the nanoparticles in much higher concentration in the tissue of interest
which is of use for both diagnostic and therapeutic purposes.
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Gold nanoparticles show great potential for cancer targeting, as they are multifunctional.
A polymer coating can be added to the outside of the nanoparticle for purposes such as
increasing solubility. Targeting ligands can also be added, such as peptides, antibodies or
small molecules to allow accumulation of the AuNP in the target of interest. In order to
externally visualize the target, a PET isotope such as fluorine 18 can also be added for
PET imaging, or an optical agent such as a dye can be added.94-97 The surface can also be
functionalized with a drug in the form of a peptide or small molecule, as the targeting
entity will allow for drug delivery to the target of interest.98,

99

Alternatively, a

radioisotope could be attached for targeted radiotherapy.100 Finally, a near infrared (NIR)
laser or radio frequency (RF) radiation can be used for tumour ablation.101 The NIR laser
or RF radiation cause the AuNP to heat, resulting in cell death. However, if the AuNPs
are targeted, only the tumour cells should be affected. Therefore, nanoparticles can
simultaneously be targeted while still allowing for imaging or therapy (Figure 1.14).

Figure 1.14: Schematic displaying the multivalency of gold nanoparticles (adapted from
reference 102)
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1.12

Peptide Receptor Binding

Receptors are proteins that are embedded either in the plasma membrane (cell surface
receptors), cytoplasm (cytoplasmic receptors), or nucleus (nuclear receptors) of a cell.
These receptors have endogenous ligands that bind in a “lock and key” fashion, triggering
specific signaling pathways. Cells express many receptors; however each receptor-ligand
interaction triggers its own biochemical pathway, regulating many cellular functions.
Approximately 40% of all prescription pharmaceuticals on the market target G-proteincoupled receptors (GPCR).103 GPCRs represent a superfamily of cell surface receptors
known as 7-transmembrane receptors, that are present on the surface of all cells.104 They
cross the cell membrane seven times and have both intracellular and extracellular
domains. The transmembrane sections are hydrophobic and helical causing three
extracellular loops and three intracellular loops, the N-terminus is extracellular, whereas
the C-terminus is intracellular.105 Although there are over 700 different GPCRs that react
with many different ligands, only the extra- and intracellular domains differ, the overall
structure of the transmembrane helices is highly conserved.104 However, each different
kind of ligand binds to the GPCR in a unique way, with peptides binding near the surface
of the cell membrane, involving the top of the transmembrane helices, the extracellular
loops and the N-terminal chain.8, 105 GPCRs represent the largest group of cell surface
receptors on human cells and over half of these have roles in sensory events such as in
olfaction, taste and vision.104 They have also been found to have roles in many hereditary
and somatic disorders and diseases, including cancer, infertility and HIV.106
The gastrin-releasing peptide (GRP) receptor, part of the GPCR superfamily, is
overexpressed in many forms of cancer including prostate cancer, breast cancer, renal cell
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carcinoma,

lung

cancer,

colon

cancer,

gastrinoma,

endometrial

cancer

and

gastrointestinal stromal tumours.107 Its endogenous ligand is the gastrin-releasing peptide,
which is a regulatory peptide responsible for regulating functions of the gastrointestinal
and central nervous system.107 It belongs to the subgroup known as bombesin-related
peptides.
Bombesin is a 14 amino acid peptide isolated from the skin of the European fire-bellied
toad Bombina bombina.108 Bombesin has four known receptor subtypes; bombesin
receptor subtype 1 (BB1), bombesin receptor subtype 2 (BB2), bombesin receptor
subtype 3 (BB3) and bombesin receptor subtype 4 (BB4). The first three of which are
found in humans, with BB3 being an orphan receptor with no known natural ligand, and
BB4 being found only in amphibians.
Bombesin is a GRP receptor agonist.109 Once the agonist interacts with the GRP receptor
on the cell surface, the receptor-ligand complex gets internalized into the cell (Figure
1.15).110 This internalization is desirable over ligands that bind to the surface of the cell
as it increases retention of the ligand in the target tissue.111 Therefore, targeting tumours
that overexpress GRP receptors, by designing GRP or bombesin-related peptides, have
potential to be used clinically for both tumour diagnosis and therapy.
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Figure 1.15: Internalization of a GRPR agonist into a cell (adapted from reference 107)

1.13

Summary

This thesis presents research on the design and synthesis of molecular imaging agents
based on metal-organic compounds, specifically peptides with either technetium-99m for
SPECT imaging, or gold nanoparticles for targeting prostate cancer. Chapter 2 discusses
the implications of diastereomer formation when dealing with molecular imaging agents,
through the coordination of various histidine compounds with [99mTc/Re(CO)3]+.
Chapters 3 and 4 describe synthesis of cyclic peptides for use as technetium-99m based
molecular imaging agents. In Chapter 3, click chemistry is used to simultaneously cyclize
and chelate peptides with [99mTc/Re(CO)3]+, whereas a [2+1] chelation system involving
pentapeptides containing terminal histidines is used in Chapter 4. Finally, Chapter 5
focuses on using bombesin to develop targeted water-soluble gold nanoparticles for
prostate cancer targeting.
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Chapter 2

2

Investigation of Isomer Formation Upon Coordination of
Bifunctional Histidine Analogues with [99mTc/Re(CO)3]+

2.1 Introduction
A common radionuclide used in diagnostic nuclear medicine is technetium-99m; it is
incorporated in more than 80% of radiopharmaceuticals today.1 Previously, the majority
of technetium was utilized in the +5 oxidation state for targeted agents. The [Tc=O]3+
core forms complexes with square pyramidal geometry upon treatment with various
tetradentate ligand sets.2-5 However, the presence of an unprotected side adjacent to the
oxo ligand left these complexes open to protonation, which could lead to decomposition.6
The use of technetium in the +1 oxidation state was pioneered by Davison and Jones, 7
and was developed for use in targeted radiopharmaceuticals by Alberto.8-12 These
octahedral Re/Tc tricarbonyl complexes, when coordinated with a tridentate chelator, are
completely protected against ligand attack.6 Another advantage to this core is its small
size and lipophilicity, which allows for easy incorporation into the ligand structure,
therefore having little effect on biological activity.6,

13

These octahedral complexes are

generally used with tridentate chelators as they tend to form a more stable complex and
have a higher in vivo stability than bidentate chelators.14 As well, they tend to react very
fast, making them ideal for radiolabelling as the time required for synthesis can be
decreased.14



A version of this chapter has been published. Simpson, E.J.; Hickey, J.L.; Breadner, D.; Luyt, L.G.
Dalton Trans., 2012, 41, 2950-2958. - Reproduced by permission of The Royal Society of Chemistry.
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Nα-substituted histidine is a tridentate chelator capable of coordinating Re/99mTc
tricarbonyl.15-17 Histidine, as a chelator, forms complexes with many desirable properties,
such as high biological stability and specific activity, as well as the ability to coordinate
rapidly and quantitatively at low concentrations.2, 18, 19 This chelator has found use in the
labelling of many different biomolecules including neurotensin analogues, which target
pancreatic carcinoma;15,

16

bombesin analogues, which target gastrin-releasing peptide

receptors;20 and cyclic RGD peptide systems, which target the αvβ3 integrin, overexpressed in angiogenic vessels and malignant tumours.21
Once histidine is coordinated to the Re/Tc core, a neutral metal complex is created, which
has the potential to produce diastereomers. The issue of isomer formation has previously
been reported for Re/Tc chelators containing various amine-based ligand sets.22-24
However, diastereomer formation for biomolecules containing the Nα-substituted
histidine chelator has not been described. Work has been done in our lab with a cyclic
RGD peptide system containing an Nα-substituted histidine chelator (Figure 2.1). When
coordinated with Re/Tc tricarbonyl, it was found that two products were formed. These
products had the same molecular weight and, therefore, were thought to be isomers at the
alpha amine of the histidine.

Figure 2.1: Cyclic RGD peptide system containing an Nα-substituted histidine chelator
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Diastereomer formation is a significant concern in drug development as the presence of
an unwanted isomer can cause side effects, toxicity and result in differing
pharmacokinetic properties from that of the desired isomer. For this reason, there often is
increased scrutiny during regulatory approval for drugs containing diastereomers. For
example, the Food and Drug Administration (FDA) in the United States has indicated
that, “diastereomers therefore should, with the rare exception of cases where in vivo
interconversion occurs, be treated as separate drugs and developed accordingly”.25
There are examples reported of Nτ-derivatized histidine,19, 26 as well as the related 1,2,3triazole analogues,26,

27

which avoid isomer formation by leaving the Nα position as a

primary amine. As such, these metal complexes show promise for radiopharmaceutical
development. However, as the issue of diastereomer formation for Nα-substituted
histidine complexes has not been previously addressed in the literature, the focus of this
paper is the investigation of the existence and nature of the products formed upon
coordination of this chelator with the [M(CO)3]+ core. This was done through
coordination of simplified chelation models with rhenium followed by thorough analysis
by NMR spectroscopy, allowing for determination of the stereochemistry of the resultant
diastereomers.

2.2 Results and Discussion
Four different histidine chelators (Figure 2.2) were synthesized and characterized both
prior to and following coordination with rhenium tricarbonyl in order to determine the
nature of the isomers being formed. The first was a small molecule histidine chelator
synthesized by reductive amination, 2.1. This chelator was then modified with a protected
imidazole 2.2 in order to eliminate the possibility that the observed isomers were pros-
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tele (π-τ) linkage isomers of the imidazole ring. The third chelator developed was a
derivative of 2.1 with the alpha amine on the histidine methylated, 2.3, in order to
determine the role of the secondary amine in isomer formation. Finally, a modified
dipeptide 2.4 was also synthesized by solution-phase techniques, in order to compare the
role of histidine in isomer formation between the small molecule chelators and those
within a peptide-like system.

Figure 2.2: Simplified histidine chelation models used for investigation of diastereomer
formation

2.2.1

Nα-benzyl-L-histidine

As a model system, a small molecule chelator consisting of a benzylated histidine was
prepared. This was done by reductive amination of H-His(Trt)-O(tBu) and benzaldehyde
with sodium borohydride to form chelator 2.6 (Scheme 2.1).28 Chelator 2.6 could then be
coordinated with [Re(CO)3(H2O)3]OTf29 in the presence of sodium hydroxide and
methanol. This formed the final coordinated product 2.1, which precipitated out of
solution and was easily recovered by centrifugation.
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Scheme 2.1: Synthesis and coordination of chelator 2.6
Analytical LC-MS showed that two products were formed in approximately a 2:1 ratio
upon coordination (Figure 2.3a). These products were believed to be diastereomers at the
alpha amine of the histidine, as both products had the theoretical coordinated mass of
515.9/517.9 m/z (NaC16H14O5N3185/187Re) displaying the characteristic rhenium 185/187
isotopic signature. The major isomer was isolated (Figure 2.3b) by recrystallization in
acetonitrile, allowing for further experimentation.

Figure 2.3: Analytical HPLC trace, UV absorbance detected from 210-800 nm (RP-C18
4.6 x 250 mm, 5 μm), of a) the mixture of isomers of 2.1, and b) the purified major
isomer 2.1a
1

H NMR spectra of the purified product before and after coordination (Figure 2.4) was

used to confirm the presence of isomers. When comparing the two NMR spectra, it was
quite evident that [Re(CO)3]+ incorporation was successful as a large change in the
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splitting and chemical shift of the methylene protons was observed. Figure 2.4b shows
that, upon coordination of [Re(CO)3]+, all peaks were doubled, which indicated that there
were two diastereomers formed.

Figure 2.4: Methylene region of the 1H NMR (400 MHz, MeOH-d4) of a) the
uncoordinated product 2.6, b) the coordinated mixture of 2.1, and c) the pure major
isomer 2.1a
The major isomer was successfully isolated from the mixture and 1H (Figure 2.4c),

13

C,

gCOSY, and NOESY NMR studies were performed. Through the NOESY experiment
(Figure 2.5), the structure of the major isomer was determined based on the throughspace correlations of the protons. Of particular interest was the interaction of the protons
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on carbon C as well as the amine proton with the protons on carbon A. There is a
correlation that can be seen between the amine proton and the A proton (solid circle on
Figure 2.5), while no correlation is seen between the C protons and the A protons (dashed
circle on Figure 2.5). This leads to the conclusion that the major isomer has the
stereochemistry indicated as 2.1a (Figure 2.6).

Figure 2.5: NOESY spectrum (400 MHz, MeOH-d4) of the pure major isomer of 2.1
showing correlation between the proton on carbon A and the amine proton (solid circle)
and the lack of correlation between protons on carbons A and C (dashed circle)

2.2.2

Stability Studies

In order to determine the stability of the complex, the purified major isomer 2.1a was
dissolved in MeOH under either neutral, acidic (0.1 M HCl) or basic (0.1 M NaOH)
conditions and monitored by HPLC to see if the isomers interconvert in solution (Figure
2.6).
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Figure 2.6: Stereochemistry of the major isomer 2.1a as determined by gCOSY and
NOESY experiments and interconversion of the major isomer 2.1a to the minor isomer
2.1b
In neutral solution no interconversion between isomers was detected at room temperature
after 48 h. However, upon heating to approximately 35oC for 24 h, the isomers
interconverted to their former ratio of approximately 2:1. Under acidic conditions (0.1 M
HCl) there was no interconversion detected after 48 h. Upon heating, 2.1a decomposed,
rather than interconverting to the minor isomer. When 2.1a was put into 0.1 M NaOH it
immediately interconverted to the previous ratio. This ratio remained unchanged after
stirring at room temperature for 48 h, followed by heating for 48 h. Since the
interconversion occurred under both neutral and basic conditions, it can be concluded that
the isomer formation is not due to epimerization at the alpha carbon upon addition of
base during metal coordination.

2.2.3

Technetium-99m Labelling of Nα-benzyl-L-histidine

The small molecule chelator 2.6 was labelled with technetium-99m to give 2.7 (Figure
2.7). Addition of pertechnetate to a commercially available Isolink kit30 formed the
[99mTc(CO)3(H2O)3]+ starting material. This reduced Tc-99m was then added to a solution
of 2.6 to form the radiolabelled histidine derivative 2.7. The analytical HPLC gamma
trace revealed two peaks at the same retention time as the rhenium analogue; these two
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peaks also appear in the same ratio as seen when 2.6 is coordinated with rhenium (Figure
2.7).

Figure 2.7: Analytical HPLC gamma trace (C18 4.6 x 150 mm, 5 μm) of
2.7

99m

Tc labelled

From this, it could be seen that 2.6 was successfully labelled with [99mTc(CO)3]+ and
formed a mixture of two isomers in a similar fashion to that seen upon rhenium
coordination.

2.2.4

Histidine Linkage Isomers

It was recently reported in the literature that histidine can form pros-tele (π-τ) linkage
isomers with palladium and ruthenium, in a square planar arrangement, where the
coordination can be to either of the imidazole N-atoms on the histidine.31, 32 In order to
ensure that the observed isomers were, in fact isomers at the secondary amine, a protected
version of 2.6 was synthesized (Scheme 2.2). It was prepared in the same manner as 2.6,
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with the exception that the histidine contained a methyl ester instead of a tert-butyl ester,
which is an orthogonal protecting group to the trityl group present on the imidazole. This
allowed for selective deprotection of the methyl ester prior to coordination, while leaving
the trityl group intact. This experimental design would eliminate the possibility that the
observed isomers were pros-tele (π-τ) linkage isomers, given that only the unprotected
imidazole nitrogen is able to coordinate to the rhenium.

Scheme 2.2: Coordination of 2.8 with [Re(CO)3]+ to form 2.2, a modification of 2.1 with
a trityl protected imidazole to demonstrate that the isomers are formed at the secondary
amine, as opposed to linkage isomers of the imidazole
Chelator 2.8 was synthesized by the same method as was previously used for 2.5, with
the only difference being the protecting group on the histidine. Once purified by
preparative TLC, a one-pot deprotection and subsequent coordination using
[Re(CO)3(H2O)3]OTf was performed in a mixture of methanol and water at reflux.
Analysis by LC-MS again showed two peaks, both with the same mass of 759.2/761.2
m/z, which matches the theoretical mass (NaC35H28N3O5185/187Re) of complex 2.2. As the
imidazole was still trityl protected, this shows that the two products formed upon
coordination are not linkage isomers of the histidine.

2.2.5

Methylation of Nα-benzyl-L-histidine

In order to determine the role of the secondary amine in the formation of diastereomers,
another chelation model, where 2.6 is methylated at the alpha amine, was developed. This
chelator was prepared starting from 2.5 (Scheme 2.3). Through treatment with
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paraformaldehyde, the alpha amine of the histidine was methylated, giving 2.9.
Following TFA deprotection and rhenium coordination, the desired complex 2.3 was
obtained in a 62% yield.

Scheme 2.3: Synthesis of methylated complex 2.3
Through LC-MS analysis of 2.3, two products were observed to have formed, as was
seen with 2.1. Although the peaks were not fully resolved, it could be seen that both
products had the same molecular weight and rhenium signature. However, it appeared as
though one diastereomer was much more predominant than in the non-methylated version
2.1. This was most easily seen in the 1H NMR of the mixture of isomers, where, by
integration, there was approximately a 5:1 ratio (Figure 2.8). Although separation of the
isomers was not possible, further characterization including gCOSY and NOESY spectra
were performed on the mixture (see Appendix A). The NOESY spectrum confirmed the
identical major isomer that was formed previously for 2.1, as determined by the lack of a
through-space correlation between the protons on carbons A and C. From this, it can be
seen that the same diastereomers are still formed when the alpha amine is methylated.
Therefore, isomer formation is not due to the fact that the amine in 2.1 is secondary. This
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also leads to the possibility of controlling isomer formation through substitution at the
amine in order to obtain a predominant product.

Figure 2.8: Methylene region of 1H NMR (400 MHz, MeOH-d4) of 2.3. Isomers can still
be seen even when the secondary amine is methylated; however, one isomer is much
more predominant
The histidine chelator is generally reported in the literature as forming a single product
upon coordination. As the retention times of the isomers of 2.1 and 2.3 are so close by
LC-MS, two peaks could only be seen when using certain HPLC columns, whereas for
others only one peak could be seen. The column and size of molecule used when studying
this chelation system are potential reasons as to why a single product is commonly
reported for the histidine chelator when conjugated to a biomolecule.17

2.2.6

Nα-Histidinyl-acetyl-phenylalanine-OMe

In order to compare the formation of coordination isomers between a small molecule
chelator and a peptide-like chelator, a modified dipeptide was prepared by solution-phase
synthesis (Scheme 2.4).
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Scheme 2.4: Synthesis of dipeptide complex 2.4
A methyl ester protected phenylalanine was used as the first amino acid in this dipeptide.
The coupling of the phenylalanine to bromoacetic acid was attempted using three
different coupling reagents: (i) diisoproylcarbodiimide (DIC), (ii) 1-ethyl-3-(3dimethylaminopropyl) carbodiimide (EDC), and (iii) dicyclohexylcarbodiimide (DCC). It
was found that coupling using DIC gave a mixture of the bromide and chloride
analogues, with the bromide being the major component; while coupling with EDC gave
the same mixture, but with the chloride analogue being the major component. Coupling
using DCC gave approximately a 50:50 mixture of the two. The mixture prepared using
DIC could not be purified to eliminate the diisopropyl urea side product, and DCC was
not ideal to work with. For these reasons, EDC was chosen as the preferred coupling
reagent for the reaction. After purification of the bromide-chloride substituted mixture, a
Finkelstein reaction was performed to exchange the mixture of chloride and bromide
leaving groups for iodine to make 2.11. The iodo derivative then underwent a substitution
reaction with H-His(Trt)-O(tBu) as in the synthesis of 2.5, followed by TFA treatment to
afford trityl deprotection. With the methyl ester protecting group still intact, 2.12 was
then purified by preparative HPLC.
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Given that the dipeptide contains a base-labile methyl ester protecting group, the
coordination could not be done under the same conditions as was used for 2.1 and 2.3.
Therefore, coordination was performed by substituting NaHCO3 for NaOH (Scheme 4).
The rhenium product 2.4 precipitated out of solution and was collected by centrifugation.
By LC-MS it was clear that two products were again formed upon coordination, each
with the same mass (C21H22N4O8185/187Re, 644.1/646.1 m/z) and the expected isotopic
rhenium signature. The isomers were separated by preparative HPLC, and NMR studies
including 1H, gCOSY and ROESY spectra were performed. Through the ROESY
spectrum (Figure 2.9), the same through-space correlation between the protons on carbon
A and the amine proton could be seen. As well, there was a lack of correlation between
the protons on carbons A and C. Therefore, it can be seen that diastereomers also form in
a peptide-like system with the same predominant isomer as in 2.1 and 2.3.

Figure 2.9: ROESY spectrum (600 MHz, DMF-d7) of the pure major isomer of 2.4
showing correlation between the protons on carbon A and the amine proton (solid circle)
and the lack of correlation between protons on carbons A and C (dashed circle)
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2.3 Conclusions
Histidine is well suited as a chelator for the radiolabelling of peptides by coordination of
rhenium or technetium-99m. It can be used in histidine tags, which consist of repeating
linear sequences of histidine attached to the end of a protein in order to incorporate
technetium.33-39 However, a new challenge has been presented when using histidine as a
tridentate chelator as multiple products are formed upon metal complexation. Two
products can be seen in both small molecule and peptide-like systems. Through
protecting group manipulation, it was determined that the isomers were not linkage
isomers of the imidazole, but rather isomers at the alpha amine. When the secondary
amine is methylated, the isomers are still present, yet the ratio is more favoured towards
one isomer than in the non-methylated version. From gCOSY, NOESY and ROESY
experiments, the stereochemistry of the major and minor isomers of 2.1, 2.3 and 2.4 were
determined (Figure 2.10).

Figure 2.10: Stereochemistry of the diastereomers of 2.1, 2.3 and 2.4
The formation of diastereomers in any radiopharmaceutical is a major concern as
regulatory approval of drugs is more difficult when isomers are involved. Therefore, it is
critical that the formation of diastereomers be addressed when dealing with this chelation
system for the coordination of [99mTc/Re(CO)3]+.
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2.4 Experimental
Materials and Methods
All chemicals were purchased from Sigma-Aldrich, Novabiochem, Peptides International
and Chem-Impex and were used without further purification unless indicated. Isolink kits
were a generous gift from Mallinckrodt Medical. Dry CH2Cl2 was prepared by distillation
from CaH under argon. For LC-MS, a Waters, Inc. system was used, consisting of a
Waters 2998 Photodiode Array Detector and a Waters 2767 Sample Manager. For
analytical LC-MS studies, a Sunfire RP-C18 4.6 x 250 mm, 5 μm column and a Waters
Symmetry RP-C18 4.6 x 150 mm, 5 Å column were used. For preparative LC-MS work,
a Sunfire RP-C18 19 x 150 mm, 5 μm column was used. In both cases, absorbance was
detected at wavelengths of 220 nm and 254 nm. A gradient solvent system consisting of
CH3CN + 0.1% of TFA (solvent A) and H2O + 0.1% of TFA (solvent B) was used.
Silicycle Silica Gel 60 (230-400 mesh) was used for flash column chromatography
purification. EMD Silica Gel 60 F254 plates were used for analytical TLC, and EMD
Silica Gel 60 F254, 2 mm glass plates were used for preparative TLC. Varian Mercury 400
and Varian INOVA 400 and 600 NMR spectrometers were used for 1H,
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C, gCOSY,

NOESY and ROESY NMR studies. Chemical shifts are reported in parts per million
(ppm) relative to TMS (0.00 ppm). For electron impact (EI) mass spectra a Finnigan
MAT 8400 mass spectrometer was used and for electro-spray ionization (ESI) mass
spectra a Micromass Quattro Micro API mass spectrometer was used.
Nα-benzyl-L-histidine(Trt)-O(tBu) (2.5)
The HCl salt of H-His(Trt)-O(tBu) was extracted using 0.1 M Na2CO3 aqueous solution
and CH2Cl2 to give the neutral histidine (1.23 g, 2.71 mmol), which was subsequently
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dissolved in 20 mL methanol followed by the addition of 1.05 equivalents of
benzaldehyde (287 µL, 2.85 mmol). This mixture was stirred at room temperature and
reaction completion was followed by TLC. Formation of the imine was complete after 2
h, at which point 1.05 equivalents NaBH4 (108 mg, 2.85 mmol) was added. This was
allowed to stir at room temperature for 18 h. The methanol was removed with a rotary
evaporator and the resulting oil was extracted from water with CH2Cl2 and then washed
with de-ionized water (3 x 5 mL). The organic layers were filtered through cotton, and
the solvent was removed on a rotary evaporator. This resulted in a 90% yield of 2.5 (1.33
g, 2.44 mmol). HRMS: m/z calculated for C36H38N3O2, 544.2964; observed [M+H]+
544.2965. 1H-NMR Spectrum (400 MHz, CDCl3, δ): 7.35 (1H, d, imidazole, 4JH-H = 1.4
Hz), 7.11-7.31 (20H, m, ar) 6.65 (1H, d, imidazole, 4JH-H = 1.2 Hz), 3.83 (1H, d,
PhCH2N, 2JH-H = 12.9 Hz), 3.65 (1H, d, PhCH2N, 3JH-H = 12.9 Hz), 3.50 (1H, dd,
NCHCO2(CH3)3, 5JH-H = 1.4 Hz, 2JH-H = 5.9 Hz), 2.97 (1H, dd, NHCHCH2, 3JH-H = 5.7
Hz, 2JH-H = 14.5 Hz), 2.83 (1H, dd, NHCHCH2, 3JH-H = 7.2 Hz, 2JH-H = 14.5 Hz), 1.41
(9H, s, CO2C(CH3)3).
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C-NMR Spectrum (100 MHz, CDCl3, δ): 173.6 (CHC(O)O),

142.4 (ar), 140.1 (ar), 138.2 (imidazole), 137.4 (ar), 129.7 (ar), 128.1 (ar), 128.1 (ar),
127.9 (ar), 127.8 (ar), 126.7 (ar), 119.2 (imidazole), 80.6 (NCPh3), 75.0 (CO2C(CH3)3),
61.1 (NCHCO2(CH3)3), 51.8 (PhCH2N), 32.2 (NHCHCH2), 28.0 (CO2C(CH3)3).
Nα-benzyl-L-histidine (2.6)
Purified 2.5 (1.33 g, 2.44 mmol), was then deprotected in CH2Cl2 (6 mL) with
trifluoroacetic acid (TFA) (6 mL). Two equivalents of triethylsilane (866 µL, 5.42 mmol)
was added as a scavenger for the trityl protecting group. This was stirred at room
temperature for 4 h. The solution was then concentrated on a rotary evaporator and the
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trityl by-product was removed by filtration. No further purification was necessary. This
resulted in 323 mg (54%) of 2.6. HRMS: m/z calculated for C13H16O2N3, 246.1243;
observed [M+H]+ 246.1247. 1H-NMR Spectrum (400 MHz, MeOH-d4, δ): 8.83 (1H, s,
imidazole), 7.43-7.53 (6H, m, ar and imidazole) 4.24-4.35 (3H, m, PhCH2N and
NCHCO2H), 3.50 (1H, dd, NHCHCH2, 3JH-H = 5.5 Hz, 2JH-H = 15.6 Hz), 3.42 (1H, dd,
NHCHCH2, 3JH-H = 7.8 Hz, 2JH-H = 15.6 Hz). 13C-NMR Spectrum (100 MHz, MeOH-d4,
δ): 171.1 (CHC(O)O), 135.3 (ar), 132.5 (imidazole), 131.2 (ar), 130.7 (ar), 130.2 (ar),
119.0 (ar), 111.4 (imidazole), 60.8 (NCHCO2H), 51.7 (PhCH2N), 26.3 (NHCHCH2).
Rhenium(I) tricarbonyl-Nα-benzyl-L-histidine (2.1)
Chelator 2.6 (323 mg, 1.31 mmol) was coordinated with 1.2 equivalents of
[Re(CO)3(H2O)3]OTf (15.7 mL of a 0.1 M solution, 1.57 mmol) and 5 equivalents of
NaOH (1.31 mL of a 5 M solution, 6.55 mmol) in a solution of methanol (3 mL) and
water (6 mL). This solution was stirred at 80oC for 2 h and was then centrifuged in order
to separate the precipitated product. The crude solid was washed with water several times
followed by centrifugation, resulting in 600 mg (88%) of 2.1. HRMS: m/z calculated for
NaC16H14O5N3185/187Re, 536.0361/538.0389; observed [M+Na]+ 536.0385/538.0333. 1HNMR Spectrum of 2.1a and 2.1b (denoted by ’) (600 MHz, MeOH-d4, δ): 8.06 (1H, s,
ReNCHNH), 8.05 (0.5H, s, ReNCHNH’), 7.34-7.47 (5H, m, ar), 7.10 (0.5H, s,
ReNCHNHCH’), 7.00 (1H, s, ReNCHNHCH), 6.74 (0.5H, d, PhCH2NH’, 3JH-H = 4.4
Hz), 6.22 (1H, dd, PhCH2NH, 3JH-H = 3.1 Hz, 3JH-H = 10.5 Hz), 4.62 (1H, dd, PhCH2NH,
3

JH-H = 4.0 Hz, 2JH-H = 14.5 Hz), 4.19 (0.5H, dd, PhCH2NH’, 3JH-H = 6.6 Hz, 2JH-H = 14.1

Hz), 4.08 (0.5H, dd, PhCH2NH’, 3JH-H = 7.9 Hz, 2JH-H = 14.1 Hz), 4.03 (1H, dd,
PhCH2NH, 3JH-H = 11.0 Hz, 2JH-H = 14.1 Hz), 3.80 (0.5H, dd, NHCHCH2’, 3JH-H = 4.4 Hz,
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JH-H = 7.9 Hz), 3.72 (1H, dd, NHCHCH2, 3JH-H = 4.0 Hz), 3.42 (0.5H, dd, NHCHCH2’,

3

JH-H = 4.8 Hz, 2JH-H = 18.5 Hz), 3.21 (1H, dd, NHCHCH2, 3JH-H = 3.5 Hz, 2JH-H = 17.1

Hz), 3.16 (0.5H, dd, NHCHCH2’, 3JH-H = 2.6 Hz, 2JH-H = 18.0 Hz), 2.96 (1H, dd,
NHCHCH2, 3JH-H = 4.0 Hz, 2JH-H = 17.1 Hz).
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C-NMR Spectrum of 2.1a (100 MHz,

MeOH-d4, δ): 184.0 (CHC(O)O), 141.3 (ar), 137.6 (imidazole), 135.0 (ar), 130.3 (ar),
130.1 (ar), 129.6 (ar), 116.7 (imidazole), 64.1 (NCHCO2), 58.5 (PhCH2N), 28.8
(NHCHCH2).
Technetium(I) tricarbonyl-Nα-benzyl-L-histidine (2.7)

99m

To an Isolink kit containing sodium tartrate, sodium tetraborate, sodium carbonate, and
sodium boranocarbonate, 13.71 mCi (0.5 mL) of [99mTc]-pertechnetate was added and the
syringe rinsed with 0.5 mL water. This was stirred at 75oC for 30 min, then 0.7 mg of 2.6
was dissolved in 0.5 mL of the solution and stirred at 90oC for 1 h. HPLC analysis
showed retention time of 9.8 min and 10.8 min for 2.7 at a linear gradient of 20-40%
solvent A in B for 15 min. HPLC analysis of 2.1a showed retention time of 10.8 min for
the same gradient system.
Nα-benzyl-L-histidine(Trt)-OMe (2.8)
H-His(Trt)-OMe.HCl was neutralized by stirring at room temperature in CH2Cl2 along
with 1 eq NEt3 for approximately 20 min. This was then extracted with water and the
organic layers were concentrated and dried under vacuum to yield 144 mg of neutralized
starting material. The same synthetic procedure was used as with 2.6; however, a
preparative TLC plate was run as a final purification step in a solution of 95% CH2Cl2,
4% MeOH, and 1% NEt3. This yielded 47 mg (27%) of 2.8. ESI+ MS: m/z calculated for
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C33H33N3O2, 503.3; observed [M+H]+ 503.9

1

H-NMR Spectrum (400 MHz, CDCl3, δ):

7.31 (1H, s, imidazole), 7.04-7.26 (20H, m, ar), 6.52 (1H, s, imidazole), 3.78 (1H, d,
PhCH2NH, 2JH-H = 13.3 Hz), 3.56-3.62 (5H, m, PhCH2NH, NHCHCO2Me, and CO2Me),
2.88 (2H, dd, NHCHCH2, 3JH-H = 5.9 Hz).
Rhenium(I) tricarbonyl-Nα-benzyl-L-histidine(Trt) (2.2)
The methyl ester protected 2.8 (47 mg, 0.094 mmol) was dissolved in MeOH (6 mL) and
H2O (3 mL) and added 5 eq (94 μL of a 5 M solution, 0.47 mmol) of NaOH, this was
stirred at room temperature for 1 hour. To this solution was added 1.2 eq of
[Re(CO)3(H2O)3]OTf (1.13 mL of a 0.1 M solution, 0.11 mmol) and the mixture was
stirred at reflux for 2 hours. The solution was then lyophilized to yield a white powder.
After dissolving the powder in acetonitrile, the product precipitated out of solution with
the addition of water. After centrifugation, the liquid was decanted off and the remaining
solid was washed with water, giving 15 mg (21%) of 2.2. HRMS: m/z calculated for
NaC35H28N3O5185/187Re, 778.1457/780.1485; observed [M+Na]+ 778.1475/780.1521. 1HNMR Spectrum of isomers of 2.2 (minor isomer denoted by ’) (400 MHz, CDCl3, δ):
7.60 (1.5H, s, imidazole and imidazole’), 6.95-7.27 (27H, m, ar), 4.48 (1H, d, PhCH2NH,
2

JH-H = 14.1 Hz), 4.16 (0.4H, d, PhCH2NH’, 2JH-H = 13.3 Hz), 3.94 (1H, d, PhCH2NH,

2

JH-H = 14.1 Hz), 3.84 (0.4H, d, PhCH2NH’, 2JH-H = 13.3 Hz), 3.69 (1.3H, m,

NHCHC(O)), 3.32 (0.4H, dd, NHCHCH2’, 3JH-H = 3.5 Hz, 2JH-H = 18.0 Hz), 3.16 (1H, dd,
NHCHCH2, 3JH-H = 3.9 Hz, 2JH-H = 18.4 Hz), 3.02 (0.4H, dd, NHCHCH2’, 3JH-H = 3.9 Hz,
2

JH-H = 10.6 Hz), 2.60 (1H, dd, NHCHCH2, 3JH-H = 3.9 Hz, 2JH-H = 18.0 Hz)
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Nα-benzyl(methyl)-L-histidine(Trt)-O(tBu) (2.9)
The HCl salt of H-His(Trt)-O(tBu) was extracted using 0.1 M Na2CO3 aqueous solution
and CH2Cl2 to give the neutral histidine. The neutral histidine (935 mg, 2.06 mmol) was
dissolved in 20 mL methanol to which 1.05 equivalents of benzaldehyde (219 µL, 2.17
mmol) was added. This was stirred at room temperature and the reaction progress was
followed by TLC. The reaction was complete after 2 h, at which point 1.05 equivalents
NaBH4 (82 mg, 2.17 mmol) was added. This was allowed to stir at room temperature for
18 h followed by the addition of one equivalent of powder paraformaldehyde (185 mg,
2.06 mmol). Upon complete dissolution (approximately 18 h), 1.05 equivalents of NaBH4
(82 mg, 2.17 mmol) was added. After allowing to react overnight, the solution was
concentrated with a rotary evaporator and the resulting oil was extracted from water with
CH2Cl2 and then washed with de-ionized water (3 x 5 mL). The organic layers were
filtered through cotton, and concentrated on a rotary evaporator. The resulting product
was purified using flash column chromatography with an eluent of 98:1:1
CH2Cl2:MeOH:NEt3, resulting in a 67% yield of 2.9 (772 mg, 1.38 mmol). HRMS: m/z
calculated for C37H39N3O2, 557.3042; observed [M+H]+ 557.3032. 1H-NMR Spectrum
(400 MHz, CHCl3, δ): 7.15-7.40 (21H, m, imidazole and ar), 6.67 (1H, d, imidazole, 5JHH

= 1.2 Hz), 3.81 (1H, d, PhCH2N, 2JH-H = 13.7 Hz), 3.71 (1H, d, N(CH3)CHCO2(CH3)3,

2

JH-H = 7.2 Hz), 3.67 (1H, d, PhCH2N, 3JH-H = 13.7 Hz), 3.09 (1H, dd, N(CH3)CHCH2,

3

JH-H = 8.0 Hz, 2JH-H = 14.7 Hz), 2.93 (1H, dd, N(CH3)CHCH2, 3JH-H = 7.0 Hz, 2JH-H =

14.7 Hz), 2.28 (3H, s, CH2N(CH3)CH), 1.47 (9H, s, CO2C(CH3)3).
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Nα-benzyl(methyl)-L-histidine (2.10)
Chelator 2.9 (772 mg, 1.38 mmol) was then deprotected with CH2Cl2 (6 mL) and TFA (6
mL). Two equivalents of triethylsilane (446 µL, 2.76 mmol) were added as a scavenger
for the trityl group. After stirring for 4 hours at room temperature, the solution was
concentrated on a rotary evaporator, at which point the oil was dissolved in acetonitrile.
With the addition of water the trityl by-product precipitated out of solution and was
filtered off and the filtrate was lyophilized to give the final product. No further
purification was necessary. This resulted in 272 mg (76%) of 2.10. HRMS: m/z
calculated for C14H17N3O2, 259.1321; observed [M+H]+ 259.1329. 1H-NMR Spectrum
(400 MHz, MeOH-d4, δ): 8.85 (1H, s, imidazole), 7.07-7.55 (6H, m, NCH2Ph and
imidazole), 4.52 (1H, d, NCH2Ph, 2JH-H = 12.7 Hz), 4.40 (2H, m, NCH2Ph and
NCHCO2H), 3.61 (1H, dd, NCHCH2, 3JH-H = 3.7 Hz, 2JH-H = 14.9 Hz), 3.51 (1H, dd,
NCHCH2, 3JH-H = 9.8 Hz, 2JH-H = 14.9 Hz), 2.92 (3H, s, PhCH2N(CH3)).
Rhenium(I) tricarbonyl-Nα-benzyl(methyl)-L-histidine (2.3)
The histidine chelator 2.10 (272 mg, 1.05 mmol) was coordinated with 1.2 equivalents of
[Re(CO)3(H2O)3]OTf (12.6 mL of a 0.1 M solution, 1.26 mmol) and 5 equivalents of
NaOH (1.05 mL of a 5 M solution, 5.25 mmol) in a solution of methanol (3 mL) and
water (6 mL). This was stirred at 80oC for 2 h. The coordinated product precipitated and
was collected by centrifugation and washed with water. This resulted in 342 mg (62%) of
2.3. HRMS: m/z calculated for NaC17H16O5N3185/187Re, 550.0518/552.0546; observed
[M+Na]+ 550.0524/552.0539. 1H-NMR Spectrum of isomers of 2.3 (minor isomer
denoted by ’) (400 MHz, MeOH-d4, δ): 8.14 (0.2H, s, imidazole’), 8.11 (1H, s,
imidazole), 7.39-7.50 (5H, m, ar), 7.18 (0.2H, s, imidazole’), 7.05 (1H, s, imidazole),
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4.78 (1H, d, PhCH2N(Me), 2JH-H = 13.5 Hz), 4.43 (1H, d, PhCH2N(Me), 2JH-H = 13.5 Hz),
4.38 (0.2H, d, PhCH2N(Me)’, 2JH-H = 7.0 Hz), 3.94 (0.2H, dd, N(Me)CHCH2’, 3JH-H = 4.9
Hz, 2JH-H = 15.6 Hz), 3.79 (1H, dd, N(Me)CHCH2, 3JH-H = 3.3 Hz, 3JH-H = 4.9 Hz), 3.38
(0.2H, dd, N(Me)CHCH2’, 3JH-H = 4.7 Hz, 2JH-H = 18.6 Hz), 3.18 (1H, dd, N(Me)CHCH2,
3

JH-H = 3.1 Hz, 2JH-H = 18.8 Hz), 3.07 (1H, dd, N(Me)CHCH2, 3JH-H = 4.8 Hz, 2JH-H = 18.6

Hz), 2.85 (3H, s, N(Me)CHCH2).

13

C-NMR Spectrum (100 MHz, MeOH-d4, δ): 183.7

(CHC(O)O), 141.5 (ar), 133.9 (imidazole), 133.5 (ar), 132.0 (ar), 130.4 (ar), 129.7 (ar),
116.6 (imidazole), 73.1 (NCHCO2), 63.3 (PhCH2N), 45.7 (PhCH2N(CH3)), 26.1
(NHCHCH2).
N-iodocarbonyl-O-methyl phenylalanine (2.11)
H-Phe-OMe.HCl (520 mg, 2.41 mmol) was neutralized by stirring in CH2Cl2 with 1
equivalent of triethylamine (336 µL, 2.41 mmol) at room temperature for approximately
30 min. 1.1 eq of bromoacetic acid (37 mg, 2.65 mmol) was then pre-activated with 1.1
eq of EDC (411 mg, 2.65 mmol) in CH2Cl2 for approximately 5 min. This solution was
added to the reaction mixture and allowed to stir at room temperature overnight. The
crude solution was concentrated on a rotary evaporator. This was then purified using
flash column chromatography using an eluent system of 99% CH2Cl2 and 1% MeOH.
The column yielded 330 mg of crude 2.11. This was dissolved in acetone and 1.1 eq of
NaI (213 mg, 1.41 mmol) was added. The solution was refluxed overnight. The solid
NaCl could then be filtered off, and the resulting filtrate concentrated on a rotary
evaporator and dried under high vacuum, to yield 236 mg (0.68 mmol, 53%) of 2.11.
HRMS: m/z calculated for C12H14INO3, 347.0018; observed [M+H]+, 347.0022. 1H-NMR
Spectrum (400 MHz, MeOH-d4, δ): 7.20-7.29 (5H, m, CHCH2Ph), 4.63 (1H, dd,
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PhCH2CH, 3JH-H = 5.5 Hz, 3JH-H = 8.6 Hz), 3.69 (5H, m, OCH3 and C(O)CH2I), 3.14 (1H,
dd, PhCH2CH, 3JH-H = 5.5 Hz, 2JH-H = 14.1 Hz), 2.97 (1H, dd, PhCH2CH, 3JH-H = 8.6 Hz,
2

JH-H = 14.1 Hz).

Nα-histidinyl-acetyl-phenylalanine (2.12)
From the previous step, 2.11 (236 mg, 0.68 mmol) was used without further purification.
To this, 1.1 eq of neutralized H-His(Trt)-O(tBu) (341 mg, 0.75 mmol) was added in
CH2Cl2 and refluxed for 48 h. The solution was then concentrated on a rotary evaporator
and dried on high vacuum, which yielded 529 mg of the crude protected 2.12. The crude
material was then purified by flash column chromatography using an eluent system of
92% CH2Cl2, 7% MeOH and 1% NEt3. This yielded 250 mg (0.37 mmol, 55%) of pure
trityl protected 2.12. The trityl containing 2.12 (220 mg, 0.33 mmol) was then
deprotected using a 50:50 mixture of CH2Cl2 and TFA and 1 eq (52.2 µL, 0.33 mmol) of
triethylsilane. This was stirred at room temperature for approximately 4 h, at which point
it could be concentrated on a rotary evaporator by azeotroping with excess CH2Cl2. It was
dried on high vacuum to yield 19 mg (0.05 mmol, 15%) of 2.12. HRMS: m/z calculated
for C18H23N4O5, 375.1668; observed [M+H]+ 375.1671. 1H-NMR Spectrum (400 MHz,
MeOH-d4, δ): 8.84 (1H, s, imidazole), 7.42 (1H, s, imidazole), 7.18-7.29 (5H, m, ar),
4.76 (1H, dd, NCHCO2H, 3JH-H = 5.1 Hz, 3JH-H = 8.6 Hz), 4.05 (1H, dd, PhCH2CH, 3JH-H
= 5.9 Hz), 3.92 (1H, d, PhCH2CH, 2JH-H = 16.0 Hz), 3.80 (1H, d, PhCH2CH, 2JH-H = 16.0
Hz), 3.70 (3H, s, MeOC(O)), 3.35 (2H, d, C(O)CH2NH, 2JH-H = 6.3 Hz), 3.18 (1H, dd,
CO2HCHCH2, 3JH-H = 5.1 Hz, 2JH-H = 13.7 Hz), 2.98 (1H, dd, CO2HCHCH2, 3JH-H = 8.6
Hz, 2JH-H = 13.7 Hz).
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Rhenium(I) tricarbonyl-Nα-histidinyl-acetyl-phenylalanine (2.4)
The purified 2.12 (19 mg, 0.05 mmol) was coordinated with 1.2 equivalents of
[Re(CO)3(H2O)3]OTf (600 µL of a 0.1 M solution, 0.06 mmol) and 5 equivalents of
NaHCO3 (21 mg, 0.25 mmol) in a mixture of methanol (3 mL) and water (6 mL). This
was stirred at 80oC for 2 h. The precipitate was collected by centrifugation and washed
with water. This resulted in 26 mg (82%) of 2.4. HRMS: m/z calculated for
C21H22N4O8185/187Re, 643.0968/645.0995; observed [M+H]+ 643.1015/645.0984.

1

H-

NMR Spectrum (600 MHz, DMF-d7, δ): 8.82 (1H, d, MeOC(O)CHNH, 3JH-H = 8.2 Hz),
8.27 (1H, t, imidazole, 4JH-H = 1.2 Hz), 7.24-7.35 (5H, m, ar), 7.21 (1H, d, imidazole, 4JH= 1.2 Hz), 6.23 (1H, dd, C(O)CH2NHRe, 3JH-H = 2.9 Hz, 3JH-H = 10.5 Hz), 4.74 (1H, m,

H

MeOC(O)CHNH), 4.01 (1H, dd, C(O)CH2NHRe, 3JH-H = 3.5 Hz, 2JH-H = 15.8 Hz), 3.86
(1H, dd, C(O)CH2NHRe, 3JH-H = 10.5 Hz, 2JH-H = 15.8 Hz), 3.69 (3H, s, MeOC(O)), 3.49
(1H, t, NHCH(O)CH2, 3JH-H = 4.1 Hz), 3.23 (2H, d, NHCH(O)CH2, 3JH-H = 2.3 Hz), 3.16
(1H, dd, PhCH2CH, 3JH-H = 5.9 Hz, 2JH-H = 14.1 Hz), 3.01 (1H, dd, PhCH2CH, 3JH-H = 9.4
Hz, 2JH-H = 14.1 Hz).
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Chapter 3

3

Click to Cyclize and Chelate

3.1 Introduction
Novel molecular imaging probes for use in the non-invasive diagnosis of many diseases
have become essential tools in diagnostic nuclear medicine. Numerous radionuclides
possess suitable characteristics for imaging purposes, the choice of which depends not
only on the desired imaging modality, biomolecule used and need for quantitation, but
also on the cost and availability. Technetium-99m not only has ideal decay characteristics
for SPECT (single photon emission computed tomography) imaging (T1/2 = 6h, 140 keV
γ-radiation), it can also be obtained from an on-site generator, making it both cost
effective and readily available.1 As such, it is currently incorporated in more than 80% of
radiopharmaceuticals, making it the most common radionuclide used in diagnostic
nuclear medicine.2
Technetium-99m in the +1 oxidation state was discovered in 19843 and began being used
for development of radiopharmaceuticals in 1996.4-8 This oxidation state became even
more popular with the discovery of the commercially available Isolink kit,9, 10 making the
synthesis of the [99mTc(CO)3(H2O)3]+ precursor straightforward with quantitative yields
and excellent radiochemical purity. These metal complexes prefer an octahedral
coordination which protects them from ligand attack, giving them a high in vivo
stability.1, 11 The facial geometry of the carbonyls allow for easy substitution of the trans
water molecules with the tridentate chelator. Tridentate chelation systems are ideal as
they tend to form more stable complexes with faster reaction times when compared to
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bidentate chelators.1 The technetium tricarbonyl core is also very small and lipophilic,
allowing it to be easily incorporated into the ligand structure.11, 12
Rhenium and technetium-99m tricarbonyl can be incorporated into biologically relevant
peptides through the use of a bifunctional chelator. As the name suggests, this chelator is
able to chelate the metal while still maintaining a point of attachment to the biomolecule.
One such bifunctional chelator is histidine, which can coordinate [99mTc/Re(CO)3]+
through the imidazole-N1.13,

14

However, in order to make histidine a tridentate

bifunctional chelator, it must be functionalized at either the imidazole-N3 or the alpha
amine. As such, these chelators involve multistep syntheses requiring protecting groups
and purification steps.15
Copper-catalyzed azide-alkyne cycloaddition (CuAAC) reactions, more commonly
referred to as “click chemistry”, have received much attention since their discovery in
2001.16, 17 This reaction uses a copper(I) catalyst to form a 1,4-disubstituted 1,2,3-triazole
from a terminal azide and a terminal alkyne. These reactions have many applications
including bioconjugation, dendrimer synthesis, combinatorial drug discovery, and of
particular interest in this chapter, peptidomimetics.18
In 2006, the group of Roger Schibli introduced the concept of “click-to-chelate”.19 They
discovered that the triazole formed from the click reaction has very similar chelation
properties to histidine functionalized at the imidazole-N3 and could therefore be
substituted in a ligand system while still maintaining the [99mTc/Re(CO)3]+ chelation.
Click-to-chelate reactions proceed in a single step without the need for protecting groups
or purification of intermediates, making it a much easier method to form a bifunctional
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chelator. The presence of the opposing clickable entity on the peptide of interest allows
for this reaction to simultaneously form a chelation site for Re/Tc tricarbonyl as a result
of triazole formation, and to also form a stable attachment of the chelator to the peptide
through the click reaction.19-22
Bifunctional chelators attach the metal complex to the biomolecule in a pendant fashion.
The addition of pendant metal complex moieties to targeting peptides has been shown to
reduce binding affinities, increase clearance time and receptor promiscuity which
generally results in lower signal-to-noise ratios and poorer image resolution and
quality.23, 24 Another method to incorporate a radionuclide into a biomolecule is through
an integrated approach. This method involves incorporating the radiometal into the
peptide backbone, thus “hiding” the metal in the biologically active region of the peptide.
This maintains the binding affinity of the peptide prior to coordination.25 One such
arrangement involves incorporation of the chelation site, and thus the metal, into the
backbone of a peptide. Linear peptides, however, are inherently flexible and do not
always have the proper conformation for interaction with receptors. Cyclic peptides, on
the other hand, offer the advantage of locking the peptide structure in a more rigid
conformation, which promotes and maintains the proper geometry for binding. Metal
complexes incorporated into the backbones of cyclic peptides not only decrease the
molecular weight of the compound due to the lack of a bulky chelator attached in a
pendant fashion, but could also help constrain the peptide, increasing the target affinity.
In general, cyclic peptides are difficult to synthesize; synthesis typically involves high
dilutions and results in very low yields.26 One method to cyclize peptides is via peptide
bond formation. However, if the peptide is small, the ring strain of the transition state can

68

occasionally be too high to overcome and the cyclization fails. In 2006 Bock et al. used
the CuAAC reaction to cyclize a tetrapeptide tyrosinase inhibitor.27 Previous attempts to
cyclize the peptide using standard peptide coupling conditions were unsuccessful. The
1,4-disubstituted 1,2,3-trizaole formed by the CuAAC reaction has been found to be a
peptide bond mimic, having similar size, planarity, hydrogen bonding capabilities and
dipole moment.27,

28

Therefore, the peptide was modified with an alkyne at the C-

terminus and an azide at the N-terminus and successful cyclization through triazole
formation using the CuAAC reaction was reported. Therefore, the CuAAC reaction
appears to be an effective method of forming similar small cyclic peptides.
This chapter describes progress towards using CuAAC to create a metal chelation site as
a result of peptide cyclization in order to facilitate incorporation of [99mTc/Re(CO)3]+
within the peptide, while at the same time locking the conformation of the
peptidomimetic. In order for this cyclization to occur, an azide modified amino acid and
alkyne modified amino acid must be placed at both the C-terminus and N-terminus of the
peptide sequence. These two functionalities can then be reacted to form a triazole while
simultaneously cyclizing the peptide. This triazole can then act as part of a chelation site
by coordinating to the metal through the N3 atom. Although this cycloaddition reaction
has been previously reported to both cyclize a peptide as well as form a chelation site for
[99mTc/Re(CO)3]+, this will be the first example of both of these operations being done
simultaneously in order to incorporate a metal within the peptide structure, allowing for a
new method for integrating rhenium and technetium-99m tricarbonyl into a peptide
structure.

69

3.2 Results & Discussion
3.2.1

Clickable Peptide Design

The design of "click-to-chelate" cyclic peptides requires many considerations. First, the
peptide needs an alkyne at one terminus of the peptide and an azide at the other so that
peptide cyclization occurs upon formation of the triazole. Second, since this triazole is to
be used to coordinate the metal, two other metal chelating moieties must be designed into
the peptide structure such that, following cyclization, they are both within suitable
accessible geometries to participate in tridentate chelation of the metal with the triazole,
as a tridentate chelator is preferred for both technetium-99m and rhenium tricarbonyl
coordination. Though there are many possible N and O metal coordinating functional
groups, these geometric restrictions severely limit the number of suitable functional
groups available for proper design. An example of a suitable N-based donating group is
an amine, either terminal or part of the peptide chain; and an example of an O-based
donor is the carboxylic acid from the C-terminus of the peptide. The third chelating group
could be added to the peptide prior to, or following cyclization; such as another
carboxylic acid or pyridine functionality. The following sections will describe the design
and synthesis of three different clickable peptide systems, which can be seen in Figure
3.1, and their chelators.
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Figure 3.1: Design of the three different clickable peptide systems described in this
chapter, where M = Re or 99mTc

3.2.2

First Clickable Peptide System

In order to create a chelation site upon cyclization, the first "click-to-chelate" cyclic
peptide design was based on a novel synthetic amino acid containing an alkyne and
another coordinating group attached to the N-terminus of the peptide. The alkyne amino
acid chosen for the first peptide system was one that contained a pyridine group. This
synthetic amino acid was synthesized by reductive amination of propargylamine and 2pyridinecarboxaldehyde, followed by addition of ethyl bromoacetate to the secondary
amine. The ethyl ester was then deprotected with KOH to give the desired alkyne
functionalized amino acid 3.3, which could be added to the N-terminus of the clickable
peptide (Scheme 3.1).
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Scheme 3.1: Synthesis of clickable chelator 3.3 for first clickable peptide system
In order to determine if the chosen chelator would coordinate [Re(CO)3]+, a model
chelation system was synthesized by clicking the protected alkyne 3.2 with benzyl azide
to form the triazole as the third coordination site (Scheme 3.2). This was then coordinated
with [Re(CO)3(H2O)3]OTf that was synthesized by literature procedure.29, 30

Scheme 3.2: Synthesis of model chelator 3.5 for first clickable peptide system
This chelation system has recently been synthesized in the literature by a different
synthetic approach with a free carboxylic acid.31 When coordinated with [Re(CO)3]+ there
is a pH dependence for whether the carboxylic acid or the triazole are coordinated to the
metal. If the pH > 9, the carboxylic acid is coordinated, and if the pH<4, the triazole is
coordinated. However, the carboxylic acid in 3.5 was protected with an ethyl ester so that
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it could not coordinate to the metal. In the first attempt to synthesize 3.5, NaHCO3 was
used as a base, however this caused deprotection of the ethyl ester, therefore creating the
potential for the carboxylic acid to coordinate instead of the triazole. In this case, two
products were seen by LC-MS analysis with the deprotected coordinated mass and
rhenium isotopic signature, demonstrating that the coordination in 3.5 was occurring by
both chelation methods. Since this system will be attached to the cyclic peptide through
formation of a peptide bond between the deprotected carboxylic acid and the amine of the
N-terminal amino acid, prior to both the click and coordination reactions, this pH
dependence of coordination should not be an issue.
When 3.5 was synthesized in the absence of base only one peak was observed by LC-MS
analysis which showed the coordinated mass and rhenium-185/187 signature of the
protected ester. Further evidence of successful rhenium coordination was obtained using
NMR spectroscopy. Comparing the methylene regions of the 1H NMR spectra of the
clicked chelators prior to (3.4) and following (3.5) rhenium coordination, a shift in all the
peaks other than those of the ethyl ester was observed, as well as a change in the proton
coupling pattern (Figure 3.2). These data, combined with the desired mass and rhenium
isotopic signature, demonstrated that the chelator was coordinated with [Re(CO)3]+.
Successful chelation of rhenium by the small molecule design indicated the this particular
chelation system was able to coordinate [Re(CO)3]+ and thus could be used in the
clickable peptide.
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Figure 3.2: Methylene region of the 1H NMR spectra for 3.4 and 3.5 showing the shift in
peaks and change in coupling pattern indicating rhenium coordination
An azide modified amino acid also needed to be synthesized in order to add the azide
functionality to the C-terminus of the peptide. The best choice of amino acid to do this is
lysine, where the amine on the side-chain can be easily converted to an azide (Scheme
3.3). Azidation of the free side chain amine was accomplished using a diazotransfer
reagent, imidazole-1-sulfonyl azide, that was first synthesized by a known literature
procedure.32 A diazotransfer reaction could then take place with Fmoc-Lys-OH to
substitute the side chain amine for an azide.
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Scheme 3.3: Synthesis of azide functionalized lysine 3.6
A clickable peptide was then synthesized through standard Fmoc solid-phase peptide
synthesis using rink amide MBHA (4-methylbenzhydrylamine) resin to give an amide at
the N-terminus. The azide functionality was added at the C-terminus through addition of
the lysine azide 3.6. The peptide was extended by adding phenylalanine, glycine and tbutyl protected serine. Finally the alkyne functionality was added through coupling of
previously synthesized alkyne amino acid 3.3. This was then clicked on resin in order to
cyclize the peptide, creating a chelation sphere identical to that of the model chelator 3.5.
Addition of the rhenium core was performed using [NEt4]2[Re(CO)3Br3],33 as
coordination was to be completed on resin to give the final cyclized coordinated peptide
3.10 (Scheme 3.4).
A small amount of the peptide was cleaved from the resin and analyzed by LC-MS after
each step of the reaction. When peptide 3.7 was cleaved from resin it showed a single
peak by LC-MS as well as the desired mass. Once alkyne 3.3 was added to the chain to
give peptide 3.8, and the peptide cleaved from the resin, there was a single peak and a
shift in retention time by HPLC; however, no peaks corresponding to the expected mass
were observed. This lack of signal corresponding to the correct peptide masses continued
after the click reaction to give peptide 3.9; however, once cleaved from resin, again a
single peak and a shift in retention time could be seen by HPLC (Figure 3.3). The lack of
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a mass spectral signal corresponding to the products was thought to be due to the lack of
an ionizable functional group on the peptide, which is discussed in the following section.

Scheme 3.4: Synthesis of first clickable peptide system with chelator 3.3

Figure 3.3: HPLC traces showing the progression of synthesis of peptide 3.9
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This trend also continued with the coordination reaction with [Re(CO)3]+ to give peptide
3.10. However, when a MALDI-MS was obtained of peptide 3.10, the desired
coordinated mass could be seen (Figure 3.4). As well, rhenium gives an isotopic signature
for its two naturally occurring isotopes 185 (37.4%) and 187 (62.6%). In this MALDIMS this approximately 2:1 isotopic signature was observed, giving promising preliminary
results that this clickable peptide system was coordinating rhenium.

Figure 3.4: MALDI-MS of final clicked peptide 3.10 showing the desired coordinated
mass and rhenium-185/187 signature
This peptide was re-synthesized several times by both solid and solution phase techniques
in order to fully characterize each intermediate. However, this synthesis was not
reproducible, and complete characterization was unsuccessful.

3.2.3

Second Clickable Peptide System

As synthesis of the first clickable peptide system became problematic with the addition of
alkyne 3.3, a second alkyne-containing synthetic amino acid chelator was designed in
order to avoid the mass spectrometry problems. This second chelator was designed with a
carboxylic acid as the extra coordinating group in place of pyridine in order to determine
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if the issues with mass spectral analysis were due to the structure of the previous chelator.
A similar synthetic route to the first artificial amino acid was followed to create the
second with a substitution of the propargylamine with tert-butyl bromoacetate, followed
by deprotection using trifluoroacetic acid (TFA) (Scheme 3.5).

Scheme 3.5: Synthesis of clickable chelator 3.12
This chelator then underwent a click reaction, as before, with benzyl azide to create a
small molecule system that contained the tridentate chelator in order to test the chelation
sphere prior to incorporation into the peptide (Scheme 3.6). The issue of pH dependence
for the coordination as discussed above31 is present for this chelation system as there are
two free carboxylic acids. However, attachment to the peptide will occur prior to metal
chelation, leaving only one free carboxylic acid for chelation, thus eliminating the
potential problem of pH dependence as both the carboxylic acid and triazole are expected
to coordinate the metal.

Scheme 3.6: Synthesis of model chelator 3.15 for the second clickable peptide system

78

Coordination of 3.14 with [Re(CO)3(H2O)3]OTf was initially performed in the presence
of NaOH and 3.15 showed two products both by NMR spectroscopy and LC-MS
analysis, each product having the expected coordinated mass and rhenium signatures.
When this system was coordinated in the absence of base, only one product was seen.
Comparison of the 1H NMR spectra prior to (3.14) and following (3.15) coordination
showed a shift in the peaks in the methylene region as well as a change in the proton
coupling patterns (Figure 3.5). Additionally, the protons on carbon C and E in 3.15 have
independent shifts as opposed to having identical shifts as seen in 3.14. LC-MS studies
also showed a single peak with the desired coordinated mass and

185/187

Re signature,

indicating it was coordinating with [Re(CO)3]+. It could therefore be concluded that this
chelator was able to coordinate [Re(CO)3]+, and thus was a suitable chelator for use in the
clickable peptide.

Figure 3.5: Methylene region of the 1H NMR spectra for 3.14 and 3.15 showing the shift
in peaks indicating rhenium coordination
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With the suitability of the second chelation system demonstrated, the second artificial
amino acid could then be incorporated onto peptide 3.7 using standard peptide coupling
procedures (Scheme 3.7). Unlike the first synthetic alkyne amino acid coupled peptide
3.8, the mass of peptide 3.16 could be seen in the mass spectrum, showing that chelator
3.12 was successfully added to the peptide. However, by LC-MS analysis there were
many other peaks in addition to the product peak. When the click reaction was attempted
on-resin almost no product and no starting material was observed. Therefore, peptide
3.16 was re-synthesized and cleaved from the resin using TFA prior to the click reaction
of the alkyne and azide. It was then purified by preparative LC-MS before moving on to
solution phase click cyclization.

Scheme 3.7: Synthesis of second clickable peptide system with chelator 3.12
The cyclization of peptide 3.16 was attempted in solution in two different ways. It was
first attempted using Cu(OAc)2 and NaAsc in a 50:50 mixture of water and t-BuOH.
Only starting material was present after 3 days at room temperature. This was still the
case after 2 days at 50oC. After 1 night at reflux there was no remaining starting material
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as indicated by LC-MS analysis, but the chromatogram had many peaks, including two
very small peaks with the mass of peptide 3.17. Due to the number of peaks with similar
retention times, this was not able to be purified.
Another cyclization method was attempted using DBU (1,8-diazabicycloundec-7-ene)
and CuBr in toluene, refluxing overnight. By LC-MS analysis no product or starting
material was observed. As the product was polar it could not be eluted on silica TLC
(thin layer chromatography) plates and could therefore not be purified by column
chromatography. As the cyclic peptide could not be isolated, coordination of this system
was not attempted.
It was speculated that perhaps the problems with obtaining a mass spectrum were due to
the peptide not being properly ionized in the mass spectrometer due to lack of protonation
sites in the peptide system and including a protonation site in the cyclic peptide would
permit detection by HPLC-ESI-MS. Therefore, two additional cyclic peptides were
synthesized that included an ionizable arginine in the peptide at the N-terminus before
either synthetic amino acids 3.3 or 3.12 were coupled to the peptide. This, however, did
not seem to help, and only caused the formation of more by-products prior to addition of
the chelator.
In order to ensure issues were not arising due to the fact that the azide functionality was
too close to the resin, to add space between the azide and the resin an additional two
peptides were synthesized that included an alanine added to the C-terminus before adding
the azide modified lysine. This peptide was then coupled with both chelators 3.3 and
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3.12. However, the addition of an alanine spacer did not appear to make any difference
for either chelation sphere.

3.2.4

Third Clickable Peptide System

Given that the two previous clickable peptide systems did not appear to be capable of
forming a cyclized and coordinated peptide, a new system needed to be developed with
an entirely different approach. In order to make the peptide unique compared to the prior
designs, the alkyne and azide were inverted, putting the alkyne at the C-terminus and the
azide at the N-terminus.
In this new approach, a lysine could be loaded onto the resin, and the peptide extended
from the ɛ-amine. As opposed to having the alkyne on the side chain of an amino acid in
the chain, the alkyne could be attached to the α-amine of the lysine. This would not only
provide a new approach, but also allow for the newly formed secondary amine of the
lysine to act as a coordinating group for the rhenium as the triazole will be formed
adjacent to it. If synthesized on Wang resin, a carboxylic acid will be formed on the Cterminus of the peptide upon cleavage from the resin resulting in a third coordination site
for rhenium, forming a tridentate chelator upon cyclization (Scheme 3.8).
For this approach to work, an alkyne modified lysine would have to be developed
(Scheme 3.9). In addition, the alpha-amine of the lysine is required as a coordinating
group, and thus needs to exist as a secondary amine as opposed to an amide. Therefore,
an alkyne would be added to the alpha-amine of lysine. This would allow for the
modified amino acid to still attach to the resin through the carboxylic acid, while leaving
the side chain amine intact for peptide chain growth.
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Scheme 3.8: Proposed synthesis of third clickable peptide system

Scheme 3.9: Attempted and proposed synthesis of alkyne modified lysine
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Multiple attempts were made to synthesize this alkyne modified lysine. An attempt was
initially made to add propargyl bromide to H-Lys(Fmoc)-OH with the carboxylic acid
unprotected (3.24), see Scheme 3.9 approach 1. However, this did not appear to be
successful as multiple by-products were formed. Therefore, the carboxylic acid had to
first be protected with a tert-butyl group that could be selectively removed prior to
coupling onto the peptide. As can be seen in Scheme 3.9 approach 2, four different sets of
reagents, each performed multiple times with varying equivalents and reaction times,
were attempted to synthesize starting material 3.25. However, this could not be
accomplished, making continuation of the proposed synthetic approach for the third
clickable peptide system in Scheme 3.8 impossible.

3.3 Conclusions
Three different clickable peptide systems were developed, each with their own unique
chelation system. Synthesis of an azide modified lysine to add the azide functionality to
the peptides was successful, as were two “click-to-chelate” alkyne modified chelators.
Their ability to coordinate rhenium(I) tricarbonyl was verified by model click and
subsequent chelation reactions. Synthesis of the first clickable peptide system had
promising preliminary results, but did not appear to be reproducible and full
characterization of the system was not possible. Incorporation of the second chelator into
the second clickable peptide system was slightly more promising than the first; however
the subsequent click and chelation reactions were unsuccessful. Therefore, a new
approach of inverting the functionalities in the clickable peptide was attempted.
However, this pathway was unsuccessful as the alkyne modified lysine starting material
could not be prepared.
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This project has been ongoing for a number of years and much effort has been put
forward to synthesize and characterize these clickable peptides. As well, many different
pathways have been proposed and attempted with minimal progress due to unforeseen
synthetic

and

characterization

difficulties.

Therefore,

while

the

proposal

of

simultaneously combining the ability of click chemistry to both cyclize a peptide and
form a chelator for [99mTc/Re(CO)3]+ appears elegant conceptually, it has proven to be
synthetically problematic and was therefore abandoned.

3.4 Experimental
Materials and Methods
All chemicals were purchased from Sigma-Aldrich, Novabiochem, Aapptec, Peptides
International and Chem-Impex and were used without further purification unless
indicated. For HPLC-MS, a Waters, Inc. system was used, consisting of a Waters 2998
Photodiode Array Detector and a Waters 2767 Sample Manager. For analytical HPLCMS studies, a Waters Atlantis RP-C18 4.6 x 150 mm, 5 μm column was used. For
preparative HPLC-MS work, a Waters Atlantis RP-C18 19 x 150 mm, 5 μm column was
used. In both cases, absorbance was detected at wavelengths of 220 nm and 254 nm. A
gradient solvent system consisting of CH3CN + 0.1% TFA (solvent A) and H2O + 0.1%
TFA (solvent B) was used. For analytical UHPLC-MS studies, a Waters, Inc. Acquity
UPLC H-Class system was used, combined with a Xevo QTof. For analytical UHPLC
studies, a Waters Acquity UPLC BEH C18 2.1 x 50 mm, 1.7 μm column was used. A
gradient solvent system consisting of CH3CN + 0.1% formic acid (solvent C) and H2O +
0.1% formic acid (solvent D) was used. A Biotage Isolera One flash chromatography
system was used for flash column chromatography purification. Silicycle Silica Gel 60
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(230–400 mesh) was used for column chromatography purification and EMD Silica Gel
60 F254 plates were used for analytical TLC. Varian INOVA 400 and 600 NMR
spectrometers were used for NMR studies. Chemical shifts are reported in parts per
million (ppm) relative to TMS (0.00 ppm). For electron impact (EI) mass spectra a
Finnigan MAT 8400 mass spectrometer was used and for electro-spray ionization (ESI)
mass spectra a Micromass Quattro Micro API mass spectrometer was used.
General Peptide Synthesis
Fully protected resin-bound peptides were synthesized manually by Fmoc solid-phase
peptide synthesis using Rink amide MBHA resin (loading 0.34 mmol/g) and all N-Fmoc
amino acids. The resin-bound peptide was treated with 20% piperidine in N,Ndimethylformamide (DMF) for 5 and 15 minutes to remove the Fmoc protecting group,
followed by washes with both DMF and dichloromethane (DCM) after each addition. All
natural Fmoc amino acids were coupled twice using 3 eq. of Fmoc amino acid, 3 eq. 2-(6chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU)
and 6 eq. N,N-diisopropylethylamine (DIPEA) in DMF for 30 min and 1 h. Modified
amino acids were coupled under the same conditions, but were left to couple overnight.
Once the linear sequence was complete a small amount of peptide could be deprotected
and cleaved from the resin by treatment with TFA containing water (2.5% v/v) and
triisopropylsilane (2.5% v/v) as scavengers for 2 h, and its identity and purity verified by
LC-MS analysis.
If the next step was to be performed on-resin, the peptide was left on the resin. However,
if the next step required solution phase synthesis, the peptide was deprotected and
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cleaved from the resin by treatment with TFA containing water (2.5% v/v) and
triisopropylsilane (2.5% v/v) as scavengers, shaking for 4 h. The peptide could then be
precipitated from the TFA solution using cold tert-butyl methyl ether (TBME) and
collected by centrifugation and decantation. The resulting peptide was dissolved in water
and lyophilized to obtain the crude peptide which could then be purified by preparative
LC-MS.
N-propargyl-pyridine-2-methylamine (3.1)
To 5 mL of acetonitrile (ACN) under argon was added 1.1 eq. propargylamine (71 μL,
1.1 mmol) and 1 eq. 2-pyridine carboxaldeyhde (95 μL, 1.0 mmol). After stirring for 5
min, 1.6 eq. sodium triacetoxyborohydride (339 mg, 1.6 mmol) was added and was left to
stir under argon overnight. The reaction was quenched with 5 M NaOH and the solvent
removed by rotary evaporation. The remaining aqueous solution was made basic by
adding 5 M NaOH and extracted with dichloromethane to give an 89% crude yield of 3.1
(130 mg, 0.9 mmol). ESI MS: m/z calculated for C9H11N2, 147.09; observed [M+H]+
147.01. 1H-NMR Spectrum (400 MHz, CDCl3, δ): 8.44 (1H, d, ar, 3JH-H = 4.3 Hz), 7.53
(1H, ddd, ar, 3JH-H = 7.8 Hz, 3JH-H = 7.8 Hz, 4JH-H = 1.9 Hz), 7.22 (1H, d, ar, 3JH-H = 7.8
Hz), 7.06-7.03 (1H, m, ar), 3.89 (2H, s, NHCH2pyr), 3.37 (2H, d, CHCCH2NH, 4JH-H =
2.3 Hz), 2.43 (1H, broad s, CHCCH2NH), 2.16 (1H, dd, CHCCH2NH, 4JH-H = 2.3 Hz).
13

C-NMR spectrum (100 MHz, CDCl3, δ): 158.58 (ar), 149.29 (ar), 136.47 (ar), 122.44

(ar), 122.09 (ar), 81.37 (HCCCH2), 71.90 (HCCCH2), 53.36 (NHCH2Pyr), 37.59
(HCCCH2).
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Ethyl-propargyl-pyridine-2-methylamino-acetate (3.2)
To 10 mL ACN was added 1 eq. 3.1 (45 mg, 0.3 mmol), 1.5 eq. triethylamine (64 μL, 0.5
mmol) and 1.2 eq. ethylbromoacetate (51 μL, 0.5 mmol). The reaction was stirred
overnight at 50oC. The ACN was removed by evaporation and the resulting oil extracted
using DCM and NaHCO3. This was then purified by column chromatography using a
solvent system of 25% ethyl acetate and 75% hexanes, resulting in a 57% yield of 3.2 (41
mg, 0.2 mmol). HR-EI-MS: m/z calculated for C13H16N2O2, 232.1212; observed [M+H]+
232.1284. 1H-NMR Spectrum (400 MHz, CDCl3, δ): 8.55 (1H, d, ar, 3JH-H = 4.3 Hz), 7.74
(1H, ddd, ar, 3JH-H = 7.8 Hz, 3JH-H = 7.8 Hz, 4JH-H = 1.6 Hz), 7.62 (1H, d, ar, 3JH-H = 7.8
Hz), 7.25-7.22 (1H, m, ar), 4.16 (2H, q, NCH2C(O)OCH2CH3, 3JH-H = 7.0 Hz), 3.98 (2H,
s, NCH2C(O)OCH2CH3), 3.55 (2H, d, CHCCH2N, 4JH-H = 2.3 Hz), 3.48 (2H, s,
NCH2pyr), 2.26 (1H, dd, CHCCH2N, 4JH-H = 2.3 Hz, 4JH-H = 2.3 Hz), 1.26 (3H, t,
NCH2C(O)OCH2CH3, 3JH-H = 7.0 Hz).

13

C-NMR spectrum (100 MHz, CDCl3, δ): 170.6

(CH2C(O)OCH2CH3), 158.2 (ar), 149.0 (ar), 136.6 (ar), 123.2 (ar), 122.2 (ar), 78.3
(HCCCH2), 73.6 (HCCCH2), 60.5 (CH2C(O)OCH2CH3), 59.3 (NHCH2Pyr), 54.2
(CH2C(O)OCH2CH3), 42.8 (HCCCH2), 14.1 (CH2C(O)OCH2CH3).
Propargyl-pyridine-2-methylamino-acetic acid (3.3)
To 10 mL ethanol was added 1 eq. 3.2 (580 mg, 2.5 mmol) and 1.5 eq. KOH (210 mg,
3.8 mmol). This was stirred at 50oC for 2 h. The solvent was removed by evaporation and
re-dissolved in water and was then neutralized using concentrated HCl. The aqueous
solution was then frozen and lyophilized. Once dry, the powder was triterated with
CHCl3, resulting in an 86% yield of 3.3 (516 mg, 2.1 mmol). HR-EI-MS: m/z calculated
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for C11H13N2O2, 205.0977; observed [M+H]+ 205.0826. 1H-NMR Spectrum (600 MHz,
CDCl3, δ): 8.44 (1H, d, ar, 3JH-H = 4.7 Hz), 7.49 (1H, dd, ar, 3JH-H = 7.6 Hz, 3JH-H = 7.6
Hz), 7.17 (1H, d, ar, 3JH-H = 7.6 Hz), 7.01 (1H, dd, ar, 3JH-H = 7.0 Hz, 3JH-H = 5.3 Hz),
3.67 (2H, s, NCH2C(O)OH), 3.23 (2H, s, CHCCH2N), 3.11 (2H, s, NCH2pyr), 2.12 (1H,
s,CHCCH2N).
1-(benzyl)triazole-pyridine-2-methylamino-acetate (3.4)
A 700 µL solution of 1:1 t-BuOH and water was made and 1 eq. 3.2 (17 mg, 0.07 mmol)
was dissolved to make a 0.1 M solution of 3.2. To this solution, 1 eq. of benzyl azide (9
µL, 0.07 mmol), 0.1 eq. Cu(OAc)2 (1 mg, 0.007 mmol) and 0.2 eq. NaAsc (3 mg, 0.014
mmol) were added and allowed to stir at room temperature for 3 nights. The reaction
mixture was extracted with ethyl acetate, and the resulting organic layer extracted with
NaCl. The solvent was then removed with a rotary evaporator and dried under high
vacuum, giving a crude yield of 68% for 3.4 (17 mg, 0.05 mmol). HR-EI-MS: m/z
calculated for C20H23N5O2, 365.4289; observed [M+H]+ 365.1838. 1H-NMR Spectrum
(400 MHz, CDCl3, δ): 8.48-8.46 (1H, m, ar), 7.66-7.62 (1H, m, ar), 7.53-7.51 (2H, m, ar),
7.35-7.29 (3H, m, ar), 7.24-7.20 (2H, m, ar), 7.16-7.13 (1H, m, ar), 5.49 (2H, s,
PhCH2N), 4.12 (2H, q, NCH2C(O)OCH2CH3,

3

JH-H = 7.0 Hz), 3.98 (4H, m,

CCH2NCH2C(O)OCH2CH3), 3.44 (2H, s, NCH2pyr), 1.23 (3H, t, NCH2C(O)OCH2CH3,
3

JH-H = 7.0 Hz).

13

C-NMR spectrum (100 MHz, CDCl3, δ): 170.9 (CH2C(O)OCH2CH3),

158.2 (ar), 148.2 (ar), 144.7 (ar), 137.3 (ar), 134.6 (NCHC(N)CH2), 129.0 (ar), 128.6 (ar),
128.0 (ar), 123.7 (ar), 123.1 (NCHC(N)CH2), 122.4 (ar), 60.5 (CH2C(O)OCH2CH3), 58.8
(NHCH2Pyr), 54.5 (PhCH2N), 54.0 (NCHC(N)CH2), 48.8 (CH2C(O)OCH2CH3), 14.2
(CH2C(O)OCH2CH3).
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Rhenium(I) tricarbonyl-1-(benzyl)triazole-pyridine-2-methylamino-acetate (3.5)
In 1.5 mL MeOH and 3 mL water, 1 eq. 3.4 (17 mg, 0.05 mmol) was dissolved, and to
this, 1.2 eq of a 0.1 M solution of [Re(CO)3(H2O)3]OTf (600 µL, 0.06 mmol) was added
and stirred at 60oC for 1.5 h. The reaction mixture was lyophilized and washed with
water resulting in an 86% yield of 3.5 (27 mg, 0.04mmol). HR-EI-MS: m/z calculated for
C23H23N5O5185/187Re, 634.1229/636.1257; observed [M+H]+ 634.1220/636.1284.

1

H-

NMR Spectrum (600 MHz, CDCl3, δ): 8.56 (1H, d, ar, 3JH-H = 5.3 Hz), 7.93 (1H, s,
triazole), 7.83 (1H, dd, ar, 3JH-H = 8.2 Hz, 3JH-H = 7.6 Hz), 7.63 (1H, d, ar, 3JH-H = 7.6 Hz),
7.34-7.31 (3H, m, ar), 7.21-7.19 (2H, m, ar), 7.16 (1H, dd, ar, 3JH-H = 6.4 Hz, 3JH-H = 7.0
Hz), 5.40 (2H, dd, PhCH2N, 2JH-H = 20.5 Hz, 4JH-H = 14.6 Hz), 5.28 (1H, d, NCH2pyr,
2

JH-H = 16.4 Hz), 4.91 (1H, d, NCHCCH2N, 2JH-H = 16.4 Hz), 4.59 (1H, d, NCH2pyr, 2JH-

H

= 16.4 Hz), 4.48 (2H, dd, NCH2C(O)OCH2CH3, 2JH-H = 16.4 Hz, 4JH-H = 9.4 Hz), 4.42

(1H, d, NCHCCH2N, 2JH-H = 16.4 Hz), 4.28 (2H, q, NCH2C(O)OCH2CH3, 3JH-H = 7.0
Hz), 1.30 (3H, t, NCH2C(O)OCH2CH3, 3JH-H = 7.0 Hz).
Fmoc-Lys(N3)-OH (3.6)
To 6 mL DMF 1 eq. Fmoc-Lys-OH.HCl (616 mg, 1.8 mmol), 1.2 eq. imidazole-1sulfonyl azide.HCl (385 mg, 2.2 mmol), 3.7 eq. NaHCO3 (473 mg, 6.7 mmol) and 0.01
eq. CuSO4.5H2O (4 mg, 0.02 mmol) were added and stirred at room temperature
overnight. The reaction mixture was diluted with 75 mL H2O and acidified from pH 7 to
4 with concentrated HCl. The aqueous solution was extracted with ethyl acetate, and the
resulting organic layer extracted with NaCl. The organic layer was dried with MgSO4,
filtered and the solvent removed with a rotary evaporator. The resulting oil was purified
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by column chromatography removing the first impurity with 100% CHCl 3 and then
flushing with 1% acetic acid in CHCl3 to collect the product. This resulted in a 54% yield
of 3.6 (380 mg, 1.0 mmol). ESI MS: m/z calculated for C21H23N4O4, 395.17; observed
[M+H]+ 395.15. 1H-NMR Spectrum (400 MHz, CDCl3, δ): 7.75 (2H, d, ar, 3JH-H = 7.4
Hz), 7.59 (2H, d, ar, 3JH-H = 7.4 Hz), 7.39 (2H, dd, ar, 3JH-H = 7.4 Hz, 3JH-H = 7.4 Hz),
7.31 (2H, dd, ar, 3JH-H = 7.4 Hz, 3JH-H = 7.4 Hz), 4.42-4.35 (3H, m, CHCH2O), 4.22 (1H,
t, NHCHCO2H, 3JH-H = 7.0 Hz), 3.31-3.27 (2H, m, CH(CH2)4N3), 2.13-2.00 (2H, m,
CH(CH2)4N3), 1.89-1.74 (2H, m, CH(CH2)4N3), 1.62-1.37 (2H, m, CH(CH2)4N3).
tert-butyl-propargyliminodiacetate (3.11)
To 10 mL ACN, 1 eq. propargylamine (256 µL, 4.0 mmol), 1.2 eq. K2CO3 (662 mg, 4.8
mmol) and 2 eq. t-butyl bromoacetate (1.18 mL, 8 mmol) were added and the solution
stirred at 90oC overnight. The solvent was removed with a rotary evaporator and the
resulting oil re-dissolved in DCM and extracted with NaCl. The solvent was again
removed by evaporation and dried on high vacuum. The crude product was purified on a
silica pad, removing the first impurity with 100% DCM and then adding 10% MeOH in
DCM to obtain product 3.11 in a 57% yield (647 mg, 2.3 mmol). ESI MS: m/z calculated
for C15H26NO4, 284.19; observed [M+H]+ 284.15. 1H-NMR Spectrum (400 MHz, CDCl3,
δ): 3.64 (2H, d, CHCCH2N, 4JH-H = 2.4 Hz), 3.42 (4H, s, NCH2C(O)OC(CH3)3), 2.22
(1H, dd, CHCCH2N, 4JH-H = 2.4 Hz), 1.45 (18H, s, NCH2C(O)OC(CH3)3).
N-propargyliminodiacetic acid (3.12)
In 6 mL DCM and 6 mL TFA 3.11 (449 mg, 1.6 mmol) was dissolved and stirred at room
temperature for 3.5 h. The reaction mixture was then azeotroped with DCM and the
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solvent removed with a rotary evaporator and dried on high vacuum. This resulted in a
70% crude yield of 3.12 (450 mg, 1.1 mmol). ESI MS: m/z calculated for C7H10NO4,
172.06; observed [M+H]+ 172.09. 1H-NMR Spectrum (400 MHz, D2O, δ): 4.25 (2H, d,
CHCCH2N, 4JH-H = 2.7 Hz), 4.11 (4H, s, NCH2C(O)OH), 3.10 (1H, dd, CHCCH2N, 4JH-H
= 2.7 Hz).
1-(benzyl)triazole-propargyliminodiacetate (3.13)
A 7 mL solution of 1:1 t-BuOH and water was made and 1 eq. 3.11 (198 mg, 0.7 mmol)
was dissolved to make a 0.1 M solution of 3.11. To the reaction mixture, 1 eq. benzyl
azide (87 µL, 0.7 mmol), 0.1 eq. Cu(OAc)2 (13 mg, 0.07 mmol) and 0.2 eq. NaAsc (28
mg, 0.14 mmol) was added and stirred at room temperature overnight. The reaction
mixture was then extracted with ethyl acetate, and the resulting organic layer extracted
with NaCl. The solvent was then removed by rotary evaporation and dried on high
vacuum. The resulting oil was purified by flash column chromatography with a gradient
solvent system of 6-50% ethyl acetate in hexanes. This resulted in a 41% yield of 13 (119
mg, 0.3 mmol). ESI MS: m/z calculated for C22H33N4O4, 417.25; observed [M+H]+
417.26. 1H-NMR Spectrum (400 MHz, CDCl3, δ): 7.49 (1H, s, triazole), 7.33-7.20 (5H,
m, ar), 5.45 (2H, s, PhCH2N), 3.96 (2H, s, NCHCCH2N), 3.38 (4H, s,
NCH2C(O)OC(CH3)3), 1.38 (18H, s, NCH2C(O)OC(CH3)3).
1-(benzyl)triazole-propargyliminodiacetic acid (3.14)
In 7 mL DCM and 7 mL TFA 3.13 (119 mg, 0.29 mmol) was dissolved and stirred at
room temperature for 3.5 h. The reaction mixture was then azeotroped with DCM and the
solvent removed with a rotary evaporator and dried on high vacuum. The resulting oil
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was purified by flash column chromatography with a gradient solvent system of 1-10%
MeOH in DCM. This resulted in a 41% yield of 3.14 (37 mg, 0.12 mmol). ESI MS: m/z
calculated for C14H17N4O4, 305.13; observed [M+H]+ 305.12. 1H-NMR Spectrum (400
MHz, MeOH-d4, δ): 8.15 (1H, s, triazole), 7.37-7.33 (5H, m, ar), 5.63 (2H, s, PhCH2N),
4.57 (2H, s, NCHCCH2N), 4.07 (4H, s, NCH2C(O)OH).
Rhenium(I) tricarbonyl-1-(benzyl)triazole-propargyliminodiacetic acid (3.15)
To 3 mL MeOH and 6 mL water, 1 eq. 3.14 (37 mg, 0.12 mmol) was added, along with 1
eq. of a 0.1 M solution of [Re(CO)3(H2O)3]OTf (1.2 mL, 0.12 mmol). The reaction
mixture was then stirred at 60oC for 1 h, after which time it was frozen and lyophilized.
The resulting powder was washed with water, resulting in an 81% yield of 3.15 (55 mg,
0.1 mmol). ESI MS: m/z calculated for C21H23N4O4, 573.06/575.06; observed [M+H]+
573.09/575.05. 1H-NMR Spectrum (400 MHz, MeOH-d4, δ): 8.12 (1H, s, triazole), 7.427.35 (5H, m, ar), 5.58 (2H, s, PhCH2N), 4.94 (1H, d, NCHCCH2N, 3JH-H = 15.6 Hz), 4.56
(1H, d, NCH2C(O)ORe, 3JH-H = 17.2 Hz), 4.43 (1H, d, NCH2C(O)ORe, 3JH-H = 17.2 Hz),
4.35 (1H, d, NCHCCH2N, 3JH-H = 15.6 Hz), 4.04 (1H, d, NCH2C(O)OH, 3JH-H = 17.2
Hz), 3.93 (1H, d, NCH2C(O)OH, 3JH-H = 17.2 Hz).
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Chapter 4

4

Cyclized Pentapeptides as [2+1] Chelation Systems for
[99mTc/Re(CO)3]+

4.1 Introduction
Cyclic peptides are increasingly of interest in the development of pharmaceutical
products due to their improved stability, conformational constraint providing enhanced
target affinity and the potential for better mimicking protein:protein interactions as
compared to small molecules. As opposed to inherently flexible linear peptides, cyclic
peptides have a locked conformation and thus maintain a desirable secondary structure,
resulting in a higher binding affinity.1 As well, they are more resistant to enzymatic
degradation, giving them a much longer in vivo half-life.2 Another method of peptide
cyclization is through metal binding using amino acid side chains that have been found to
coordinate metals in metalloproteins.
Naturally occurring metalloproteins are known to bind a variety of metals through
histidine residues, including copper in plastocyanin3 and hemocyanin,4 iron in
hemoglobin,5 and zinc in thermolysin6 and zinc fingers.7,

8

In some cases this metal

coordination through the histidine residues can influence the secondary structure of the
protein. This can be seen with the native prion protein (PrP), which can selectively bind
Cu2+ through four His residues.9 The binding mode of these four histidines with copper
determines the secondary structure of the protein. Short protein fragments (<15 amino
acids) however, are generally not thermodynamically stable enough to form helical turns
in solution.10, 11 In order to induce a turn conformation in these short protein fragments,
metal clips have been developed that can coordinate metals such as copper, palladium,
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rhodium and ruthenium. These small peptide metal clips use two histidine residues
separated by three amino acids, which stabilizes a short helical turn in aqueous
solution.12-14
Histidine can also chelate [99mTc/Re(CO)3]+ for use in molecular imaging probes as it
displays high biological stability and specific activity, and is able to coordinate rapidly
and quantitatively at low concentrations.15-17 Nα-substituted histidine has found use as a
bifunctional chelator for labelling biologically relevant peptides as targeted molecular
imaging probes.16-22 However, coordination using the secondary amine of this histidine
analogue can form diastereomers.23 To avoid isomer formation, histidine can also be used
as a bidentate or monodentate chelator. Although it has been suggested that pros-tele (π–
τ) linkage isomers of the histidine imidazole ring can form upon coordination with
palladium,12-14 it has been shown that this is not the case when coordinating Nαsubstituted histidine with [99mTc/Re(CO)3]+.23
Histidine has also been used in repeating linear sequences, known as histidine tags, to
label proteins with Tc-99m.24-30 This process involves adding a sequence of histidines to
the end of a protein in order to incorporate [99mTc(CO)3]+ and effectively label the
protein. The metal incorporation is due to the monodentate coordination with the
imidazole of two different histidines in the sequence. While histidine has shown potential
in both stabilizing turn conformations as well as coordination with technetium-99m, the
ability of technetium coordination with histidine to form a cyclic structure for use in
radiopharmaceuticals has not been investigated.
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Pentapeptides of the form Ac-HXXXH-OH have the potential to be cyclized with the two
terminal histidines coordinating [99mTc/Re(CO)3]+ in a [2+1] fashion using the imidazole
of the N-terminal histidine, and the imidazole and carboxylic acid of the C-terminal
histidine. Once a peptide is cyclized with technetium-99m, only the cyclic version will be
biologically active and have a high binding affinity, whereas the more flexible linear
peptide will not be able to bind as strongly to the target. Herein, we report on the ability
of [99mTc/Re(CO)3]+ to cyclize and coordinate a di-histidine containing pentapeptide of
the form Ac-HAAAH-OH in a [2+1] fashion, and the method by which this coordination
occurs, through NMR spectroscopy and computational studies.

4.2 Results & Discussion
In order to investigate the capability of

99m

Tc/Re tricarbonyl to form a metal clip, the

pentapeptide Ac-HAAAH-OH was synthesized and characterized both prior to and
following coordination with rhenium tricarbonyl. The peptide was designed to have two
terminal histidines capable of coordinating rhenium or technetium, as well as three
central alanine residues to aid in forming a turn in the peptide upon coordination, as
alanine rich sequences have been shown to form stable α-helices in water.31 This would
allow the peptide to coordinate the rhenium or technetium in a [2+1] fashion using the
imidazole of the N-terminal histidine, and the imidazole and the carboxylic acid of the Cterminal histidine, resulting in a neutral peptide-metal complex.
It was predicted that, due to the findings in our previous exploration of histidine
coordination with rhenium,23 the imidazole-N1 of each histidine would preferentially
coordinate to the rhenium. This coordination has also been proposed with histidine tags
where Tc-99m coordinates to the peptide through the imidazole-N1 of the histidines.32
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This method of coordination was also hypothesized through computational studies
suggesting that it is favourable for the [99mTc(CO)3]+ to be coordinated with the
imidazole-N1 of both His4 and His2 of a 5-His-tag.33 This led to the proposed structure
shown in Figure 4.1.

Figure 4.1: Proposed structure of the coordinated pentapeptide resulting in a cyclic,
neutral peptide-metal complex

4.2.1

Peptide Synthesis

The acetylated pentapeptide Ac-HAAAH-OH was assembled using standard 9fluorenylmethoxycarbonyl (Fmoc) solid-phase peptide synthesis (SPPS)34 on Wang resin
pre-loaded with histidine. The peptide was synthesized and the N-terminal amine capped
using 10% acetic anhydride in DMF. This peptide was then cleaved from the resin with
trifluoroacetic acid (TFA) and precipitated using tert-butyl methyl ether (TBME). The
peptide was then purified by preparative HPLC to give pure linear Ac-HAAAH-OH
(4.1). The peptide could then be cyclized and coordinated using [Re(CO)3(H2O)3]OTf 35,
36

(Scheme 4.1). This was done by heating the peptide in a solution of water, NaOH and

previously prepared [Re(CO)3(H2O)3]OTF. Once coordinated, the peptide was purified
by reverse-phase flash chromatography.
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Scheme 4.1: Coordination of pentapeptide 4.1 with [Re(CO)3]+ or [99mTc(CO)3]+,
resulting in cyclic peptides 4.2 and 4.3

4.2.2

Radiolabelling

Peptide 4.1 was labelled with technetium-99m to give peptide 4.3 (Scheme 4.1). Addition
of

pertechnetate

to

a

commercially

available

Isolink

kit37

formed

the

[99mTc(CO)3(H2O)3]+ starting material. The reduced Tc-99m was then added to a solution
of 4.1 to form radiolabelled 4.3. This was then purified using a Waters Sep-Pak C18 Plus
Cartridge to give a decay corrected radiochemical yield of 73%. The success of the
radiolabelling was confirmed by analytical UHPLC, where the retention time of the
radiolabelled peptide 4.3 in the gamma trace correlated well with that of the rhenium
coordinated peptide 4.2 in the UV chromatogram (Figure 4.2). From this, it could be seen
that 4.1 was successfully labelled with [99mTc(CO)3]+, forming peptide 4.3.
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Figure 4.2: UHPLC analysis showing correlation between a) UV chromatogram of
rhenium coordinated peptide 4.2, and b) gamma trace of Tc-99m labelled peptide 4.3

4.2.3

NMR Spectroscopy Studies

Through LC-MS studies, the purity and identity of the linear peptide 4.1 and coordinated
peptide 4.2 were verified. However, further structural analysis through NMR
spectroscopy was required. This was done using 1D 1H NMR, 2D 1H-1H NMR, as well as
variable temperature (VT) NMR spectroscopy to determine if any hydrogen bonding
existed in the coordinated species.

4.2.4

1

H NMR Spectroscopic Analysis

Structure elucidation of both the linear (4.1) and the cyclized (4.2) peptides was
accomplished through 1D 1H, as well as 2D g-COSY and TOCSY NMR spectroscopy
studies. Figure 4.3 shows the aromatic and methylene regions of the 1H NMR for both the
linear and coordinated peptides. When looking at the aromatic region (Figure 4.3a and b),
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it can be seen that all four histidine imidazole protons shift significantly upfield in the
coordinated peptide, as compared to the linear peptide. A considerable shift can also be
seen for both the histidine and alanine amide protons. In the methylene region (Figure
4.3c and d), a dramatic shift can be seen in the histidine and alanine CH protons in the
NMR spectrum of the coordinated peptide, when compared to that of the linear peptide.
The linear peptide displays pseudo-symmetry, causing several overlapping peaks in the
1

H NMR spectrum. However, once coordinated, a separation of peaks can be seen. This is

evident in the methylene region for the histidine and alanine CH peaks, further verifying
that the peptide is coordinated with rhenium. This overlapping of peaks can also be seen
for the imidazole peaks in the linear peptide; however, once coordinated a unique
chemical shift can be seen for all four imidazole protons. This indicates that both
histidines are coordinated to the rhenium and that the peptide cyclizes as a result of
coordination.

Figure 4.3: 1D 1H NMR of the aromatic region of a) linear peptide 4.1 and b)
coordinated peptide 4.2, as well as the methylene region of c) linear peptide 4.1 and d)
coordinated peptide 4.2 in DMSO-d6 at 600 MHz
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In order to identify individual amino acids and assign amide protons for variable
temperature NMR, g-COSY and TOCSY experiments were also performed. Through the
TOCSY NMR spectrum of the coordinated peptide 4.2, it was possible to identify which
peaks belonged to each amino acid. From the correlations of the alanine CH3 to the CH
peaks, it was possible to determine which CH peaks corresponded to alanine (A1-A3), and
by default, which were histidine (H1 and H2) CH peaks (Figure 4.4a). The identity of the
histidine CH peaks were further confirmed from the TOCSY correlations to the histidine
CH2 peaks (Figure 4.4b), allowing for assigning of individual histidines.

a)

b)

Figure 4.4: TOCSY NMR spectra of coordinated peptide 4.2 in DMSO-d6 at 600 MHz,
showing identification of a) alanine (A1-A3) CH and CH3, and b) histidine (H1 and H2)
CH and CH2 protons
From the identified CH peaks, it was then possible to assign all amide protons to specific
amino acids, as seen in Figure 4.5. With the identity of all the amide protons assigned,
VT NMR could then be used to determine which of these amide protons participated in
intramolecular hydrogen bonding. Further g-COSY and TOCSY spectra for both the
linear and coordinated peptides can be seen in Appendix A.
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Figure 4.5: TOCSY NMR spectrum of coordinated peptide 4.2 in DMSO-d6 at 600
MHz, showing identification of alanine (A1-A3) and histidine (H1 and H2) amide protons,
as well as the much larger upfield shift of the H1 amide and CH protons compared to that
of H2 (grey circles)

4.2.5

[2+1] Coordination

The 1H NMR spectra shown in Figure 4.3, shows a much larger shift in both the amide
and CH protons of one of the histidines. From the TOCSY NMR in Figure 4.5, it can be
seen that the amide and CH protons that have a larger shift both correspond to the same
histidine (H1); whereas the amide and CH protons that have a smaller shift, both
correspond to H2. A study on the coordination of histidine with rhenium was previously
published in our lab and in Chapter 2.23 In Chapter 2, a benzylated histidine was
coordinated with rhenium through the imidazole, the carboxylic acid, and the secondary
amine of the histidine. When comparing the shifts seen upon coordination, the 1H NMR
spectrum in the current study shows nearly identical changes in shift in the CH proton of
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H1 to that seen in the previous study, while the CH proton of H2 varies significantly from
that seen previously, as described in Chapter 2.
Previously, the CH proton shifted from 4.25 ppm to 3.72 ppm upon coordination; a shift
of 0.53 ppm. In the current study, the CH proton of H1 shifts from 4.52 ppm to 4.00 ppm;
a shift of 0.52 ppm. However, the CH proton of H2 only shifts from 4.56 ppm to 4.41
ppm; a shift of 0.15 ppm. This comparison in shifts suggests that H1 is the C-terminal
histidine, and that it is coordinated to the rhenium through both the imidazole and the free
carboxylic acid giving the desired [2+1] coordination of the peptide to rhenium.

4.2.6

Variable Temperature 1H NMR Spectroscopy

Once the amide peaks were assigned to individual amino acids, it was possible to
determine which of these displays intramolecular hydrogen bonding interactions. The
most common method for identifying the presence of intramolecular hydrogen bonds in a
peptide is through VT NMR spectroscopy.38-40 The chemical shifts of amide protons
involved in intramolecular hydrogen bonding will not be as sensitive to changes in
temperature as those that are not hydrogen bonded, or are intermolecularly hydrogen
bonded to the surrounding solvent. Increasing temperature causes an upfield shift in
amide protons; however, the shift is much less if the proton is hydrogen bonded. This can
be tracked quantitatively by dividing the change in shift over the change in temperature
(Δδ/ΔT), with Δδ/ΔT values that are more positive than -4.6 ppb/K corresponding to
protons that are involved in intramolecular hydrogen bonding.41, 42
VT NMR spectroscopy studies were performed on the coordinated peptide 4.2 in
dimethylsulfoxide-d6 (DMSO-d6) from 25-60oC at 5oC intervals. The series of 1H NMR
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spectra obtained can be seen in Figure 4.6. As the temperature is increased, a difference
in the magnitude of the change in shift of each individual proton can be seen. When
converted to a Δδ/ΔT value (Table 4.1), it can be seen that both histidine amide protons
as well as two of the three alanine amide protons seem to be intramolecularly hydrogen
bonded.

Figure 4.6: VT 1H NMR of coordinated peptide 4.2 in DMSO-d6 at 5oC intervals from
25-60oC at 600 MHz
Table 4.1: The Δδ/ΔT values obtained from the VT 1H NMR analysis for each amide
proton in peptide 4.2
Δδ/ΔT (ppb/K)
A2 NH

H2/A1 NH

A3 NH

H1 NH

-4.6

-3.7

-3.7

-2.0
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4.2.7

Computational Studies

In order to determine if the proposed structure in Figure 4.1 matched the results from the
VT NMR spectra, computational studies were performed for the coordinated peptide.
There is potential for the formation of four isomers upon coordination of the linear
peptide 4.1 with [Re(CO)3]+ (Figure 4.7). Two of these isomers are diastereomers (4.2a
and 4.2b), while 4.2c and 4.2d are conformational isomers of 4.2a and 4.2b, respectively,
which exist due to the restricted rotation of the macrocycle. All isomers were optimized
using density functional theory (DFT), employing the B3LYP functional.

Figure 4.7: Four possible isomers of the proposed structure for cyclized peptide 4.2,
where 4.2a and 4.2b are diastereomers, and 4.2c and 4.2d are conformational isomers of
4.2a and 4.2b, respectively
In comparing to the VT NMR spectroscopy results, we were surprised to find that the
lowest energy isomer (4.2a) revealed hydrogen bonding for only two of the alanine
amides (Figure 4.8). This was not in concordance with what was seen for the VT NMR
studies. The other three possible isomers (4.2b-d seen in Appendix A) also did not show
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the expected hydrogen bonding. Therefore, the proposed structure based upon the
expected N1 nitrogen coordination for both imidazole heterocycles did not appear to be
in agreement with the computational results.

Figure 4.8: Lowest energy isomer (4.2a) of the proposed structure of cyclized peptide
4.2 showing intramolecular hydrogen bonding interactions
As was discussed previously in Chapter 2,23 the C-terminal histidine can only coordinate
to the rhenium through the imidazole-N1 when the carboxylic acid of the histidine is also
coordinated to the rhenium in a bidentate fashion. Therefore, it is not possible for the Cterminal histidine to coordinate to the rhenium with the imidazole-N3. However, as was
seen previously with this peptide when coordinated to palladium, linkage isomers of
histidine can form when coordinated in a monodentate fashion where either the
imidazole-N1 or N3 can coordinate.12,

13

Therefore, the N-terminal histidine should be

able to coordinate rhenium with either the imidazole-N1 or N3 when coordinating in a
monodentate fashion.
Therefore, calculations were performed on a new structure where the N-terminal histidine
was coordinated to the rhenium through the imidazole-N3. This method of coordination
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gives another four possible isomers (Figure 4.9) where 4.2e and 4.2f are diastereomers,
and 4.2g and 4.2h are conformational isomers of 4.2e and 4.2f, respectively, resulting in a
possibility of eight total isomers for the [2+1] coordination.

Figure 4.9: Four possible isomers of the new proposed structure for cyclized peptide 4.2,
where 4.2e and 4.2f are diastereomers, and 4.2g and 4.2h are conformational isomers of
4.2e and 4.2f, respectively
Although three of the isomers for this new proposed structure did not show any hydrogen
bonding (4.2f-h seen in Appendix A), the lowest energy isomer (4.2e) (Figure 4.10) did
show intramolecular hydrogen bonding for both histidine amides as well as two of the
alanine amides, while one alanine amide did not display intramolecular hydrogen
bonding. This matched perfectly with what was determined from the VT NMR studies.
Therefore, it was concluded that this new proposed structure is the most likely method of
coordination for the cyclized peptide 4.2.
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Figure 4.10: Lowest energy isomer (4.2e) of the new proposed structure of cyclized
peptide 4.2 showing intramolecular hydrogen bonding interactions

4.3 Conclusions
A peptide of the form Ac-HAAAH-OH was synthesized and coordinated with
[99mTc/Re(CO)3]+ in a [2+1] fashion using the imidazole of the N-terminal histidine and
the imidazole and free carboxylic acid of the C-terminal histidine. The structure was
evaluated through 1H, g-COSY, and TOCSY NMR spectroscopy. These NMR spectra
confirmed that both histidines were coordinated to the metal in a [2+1] fashion. VT NMR
studies were completed to determine which amide protons displayed intramolecular
hydrogen bonding interactions. Computational studies showed that none of the four
possible isomers of the original proposed structure in Figure 4.1 matched the results from
the VT NMR spectra. As a result, the proposed structure was altered such that the Nterminal histidine coordinated the metal instead through the imidazole-N3. This also gave
four potential isomers, with the lowest energy isomer matching with the experimental
data from the VT NMR. This lead to the conclusion that structure 4.2e seen in Figure
4.11 is the most likely structure of the cyclized peptide.
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Figure 4.11: Structures of the two lowest energy isomers of Re(CO)3-Ac-HAAAH-OH
(4.2), with 4.2e being the most likely isomer based on VT NMR spectroscopy and
computational studies
The results from the VT NMR spectra when combined with the computational studies
gives a much better understanding of the coordination of histidine with [99mTc/Re(CO)3]+.
This discovery is important when coordinating histidine in a monodentate fashion, which
is relevant not only for coordination of these [2+1] HXXXH peptide systems, but also
when preparing His tags for radiolabelling proteins. This method of [2+1] coordination
using terminal histidines provides a quick and easy way to simultaneously cyclize and
coordinate biologically relevant peptides for use as molecular imaging probes.

4.4 Experimental
Materials & Methods
All chemicals were purchased from Sigma-Aldrich, Novabiochem, Aapptec, Peptides
International and Chem-Impex and were used without further purification unless
indicated. For LC-MS, a Waters, Inc. system was used, consisting of a Waters 2998
Photodiode Array Detector and a Waters 2767 Sample Manager. For analytical LC-MS
studies, a Waters Atlantis RP-C18 4.6 x 150 mm, 5 μm column was used. For preparative
LC-MS work, a Waters Atlantis RP-C18 19 x 150 mm, 5 μm column was used. In both
cases, absorbance was detected at wavelengths of 220 nm and 254 nm. A gradient solvent
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system consisting of CH3CN + 0.1% TFA (solvent A) and H2O + 0.1% TFA (solvent B)
was used. For analytical UHPLC-MS studies, a Waters, Inc. Acquity UPLC H-Class
system was used, combined with a Xevo QTof and a Bioscan Inc. FC-1000 Flow-Count
Radio-HPLC Detector System. For analytical UHPLC studies, a Waters Acquity UPLC
BEH C18 2.1 x 50 mm, 1.7 μm column was used. A gradient solvent system consisting of
CH3OH + 0.1% formic acid (solvent C) and H2O + 0.1% formic acid (solvent D) was
used. A Biotage Isolera One flash chromatography system was used for flash column
chromatography purification fitted with a Snap 12 g reversed phase C-18 column.
Analtech HPTLC-RP18F reversed phase plates were used for analytical TLC. Varian
INOVA 600 NMR spectrometer was used for 1H, g-COSY and TOCSY NMR studies.
Chemical shifts are reported in parts per million (ppm) relative to TMS (0.00 ppm). For
electron impact (EI) mass spectra a Finnigan MAT 8400 mass spectrometer was used and
for electro-spray ionization (ESI) mass spectra a Micromass Quattro Micro API mass
spectrometer was used.
Ac-HAAAH-OH (4.1)
Pentapeptide 4.1 was synthesized on-resin using standard Fmoc solid-phase peptide
chemistry by manual synthesis using Wang resin (0.5 mmol, loading 0.34 mmol/g) preloaded with Fmoc protected histidine. Removal of Fmoc was carried out using 20%
piperidine in DMF for 5 and 15 minutes, each followed by rinses with dichloromethane
(DCM) and N,N-dimethylformamide (DMF). Fmoc-Ala-OH was then coupled twice for
30 min and 1 h using 3 eq. of Fmoc amino acid, 3 eq. of 2-(6-chloro-1H-benzotriazole-1yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU) and 6 eq. of N,Ndiisopropylethylamine (DIPEA) in 15 mL DMF. This was repeated 2 more times with
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Fmoc-Ala-OH, followed by Fmoc-His(Trt)-OH. The peptide was then capped by
treatment with 10% acetic anhydride in DMF twice for 15 min. Once complete, the
peptide was deprotected and cleaved from the resin by treatment with TFA containing
water (2.5% v/v) and triisopropylsilane (2.5% v/v) as scavengers for 4 h. The peptide was
then precipitated from the cleavage solution by treatment with cold TBME followed by
centrifugation and decanting of the ether. Purification was performed by preparative
HPLC (linear gradient of 0-30% solvent A in B). The purity of the resultant peptide was
determined to be 95% pure by analytical LC-MS (linear gradient of 5-40% solvent A in
B). This resulted in a 56% yield of 4.1 (0.155 g, 0.28 mmol). HRMS: m/z calculated for
C23H33N9O7, 548.2581; observed [M+H]+ 548.2575. 1H-NMR Spectrum (600 MHz,
DMSO-d6, δ): 8.92 (1H, d, imidazole, 4JH-H = 1.2 Hz), 8.91 (1H, d, imidazole, 4JH-H = 1.2
Hz), 8.25 (1H, d, NH of His, 3JH-H = 7.6 Hz), 8.17 (1H, d, NH of His, 3JH-H = 8.2 Hz),
8.16 (1H, d, NH of Ala, 3JH-H = 6.5 Hz), 8.11 (1H, d, NH of Ala, 3JH-H = 7.0 Hz), 7.93
(1H, d, NH of Ala, 3JH-H = 7.6 Hz), 7.35 (1H, s, imidazole), 7.33 (1H, s, imidazole), 4.56
(1H, ddd, CH of His, 3JH-H = 8.2 Hz, 3JH-H = 5.9 Hz), 4.52 (1H, ddd, CH of His, 3JH-H =
8.2 Hz, 3JH-H = 5.3 Hz), 4.20-4.26 (3H, m, CH of Ala), 3.13 (1H, dd, CH2 of His, 2JH-H =
15.8 Hz, 3JH-H = 5.3 Hz), 3.03 (1H, dd, CH2 of His, 2JH-H = 15.3 Hz, 3JH-H = 5.9 Hz), 3.00
(1H, dd, CH2 of His, 2JH-H = 15.3 Hz, 3JH-H = 8.8 Hz), 2.91 (1H, dd, CH2 of His, 2JH-H =
15.3 Hz, 3JH-H = 8.2 Hz), 1.81 (3H, s, CH3C(O)NH), 1.21 (3H, d, CH3 of Ala, 3JH-H = 7.0
Hz), 1.18 (3H, d, CH3 of Ala, 3JH-H = 7.0 Hz), 1.17 (3H, d, CH3 of Ala, 3JH-H = 7.0 Hz).
Re(CO)3-Ac-HAAAH-OH (4.2)
Purified linear peptide 4.1 (60 mg, 0.11 mmol) was coordinated with 0.9 equivalents of
[Re(CO)3(H2O)3]OTf (990 μL of a 0.1 M solution, 0.10 mmol), using 5 equivalents of
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NaOH (109.5 μL of a 5 M solution, 0.55 mmol) in H2O (6 mL). This was stirred at room
temperature for 3 hours, followed by lyophilization. The crude coordinated peptide was
purified by reverse-phase flash chromatography (linear gradient of 12 – 100% methanol
in water). This resulted in an 82% yield of 4.2 (70 mg, 0.09 mmol). HRMS: m/z
calculated

for

C26H33N9O10185/187Re,

816.1880/818.1909;

observed

[M+H]+

816.1948/818.2047. 1H-NMR Spectrum (600 MHz, DMSO-d6, δ): 8.22 (1H, d, NH of
Ala, 3JH-H = 6.5 Hz), 8.06-8.08 (2H, m, NH of His and Ala), 7.99-8.00 (1H, m, NH of
Ala), 7.50 (1H, s, imidazole), 7.39-7.40 (2H, m, imidazole and NH of His), 6.80 (1H, s,
imidazole), 6.66 (1H, s, imidazole), 4.40 (1H, dd, CH of His, 3JH-H = 7.6 Hz, 3JH-H = 13.5
Hz), 4.28 (1H, dq, CH of Ala, 3JH-H = 7.0 Hz), 4.13-4.22 (2H, m CH of Ala), 4.00 (1H,
dd, CH of His, 3JH-H = 5.9 Hz, 3JH-H = 11.7 Hz), 2.97 (1H, dd, CH2 of His, 2JH-H = 14.7
Hz, 3JH-H = 5.3 Hz), 2.83-2.91 (2H, m, CH2 of His), 2.77 (1H, dd, CH2 of His, 2JH-H = 14.7
Hz, 3JH-H = 7.6 Hz), 1.81 (3H, s, CH3C(O)NH), 1.23 (3H, d, CH3 of Ala, 3JH-H = 7.0 Hz),
1.19 (3H, d, CH3 of Ala, 3JH-H = 7.0 Hz), 1.18 (3H, d, CH3 of Ala, 3JH-H = 7.0 Hz).
99m

Tc(CO)3-Ac-HAAAH-OH (4.3)

To an Isolink kit containing sodium tartrate, sodium tetraborate, sodium carbonate, and
sodium boranocarbonate, 1361 MBq (1.0 mL) of [99mTc]-pertechnetate was added. This
was stirred at 90oC. After 20 min, 120 µL of 1 M HCl was added and was allowed to
stand for 5 min. 272 MBq (300 µL) was then added to 4.1 (0.5 mg, 0.9 µmol) to a total
volume of 1 mL H2O. To this, 10 eq NaOH (12 µL of a 5 M solution, 9 µmol) was added
to a pH of 12, and stirred at 60oC for 30 min. UHPLC analysis showed retention time of
0.80 min for 4.3 at a linear gradient of 20-80% solvent C in D for 3 min. UHPLC analysis
of 4.2 showed retention time of 0.75 min for the same gradient system. The labelled
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peptide 4.3 was then purified using a Waters Sep-Pak Plus C18 Cartridge by eluting with
5 mL H2O and 5 mL MeOH. This resulted in a 73% decay corrected radiochemical yield.
Computational Studies
All the structures were initially constructed by DS viewer 3.5. The structures were first
optimized using semi-empirical PM6 method. Further optimizations of the structures
were performed using density functional theory (DFT), employing the B3LYP functional.
The LANL2DZ pseudopotential43-45 and the 6-31G(d) basis set were used to model
rhenium and the remaining atoms, respectively. No geometry restraint was applied during
all optimizations. The nature of the optimized structures and energy minima were defined
by subsequent frequency calculations. All calculated structures were characterized as true
minima (i.e., no imaginary frequencies). All the calculations were performed with
Gaussian 09 (RevD.01)46 on high-performance computing (HPC) facilities within the
Compute Canada network.47
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Chapter 5

5

Bombesin Functionalized Water-Soluble Gold
Nanoparticles for Prostate Cancer Targeting

5.1 Introduction
Prostate cancer is the most common cancer affecting Canadian men. It is estimated that 1
in 7 men will develop prostate cancer during their lifetime, and 1 in 28 will die from the
disease.1 If diagnosed early, the survival rate for prostate cancer is high, with the five
year relative survival ratios in Canada being 96%.2 Diagnosis of prostate cancer is
difficult as symptoms are not always present in the early stages. Two common methods
of diagnosis are the prostate specific antigen (PSA) test and the digital rectal exam. The
accuracy of these invasive methods has recently been subject to debate.3, 4 Detection of
cancer using molecular imaging offers a more accurate and non-invasive method of
diagnosis by targeting receptors overexpressed on cancer cells. Prostate cancer imaging
probes, for example, can target the overexpressed gastrin-releasing peptide receptor
(GRP-R).5, 6 This targeting of overexpressed receptors can also be used for therapeutic
purposes, as was shown by Plonowski et al., where a cytotoxic bombesin analogue was
developed that targeted GRP-R and inhibited the growth of prostate cancer.7
Gold nanoparticles (AuNPs) have recently been used for applications in cancer targeting
as they are the most stable metal nanoparticle, have low toxicity, are biocompatible, and
their surface is easily functionalized.8-12 The small size of AuNPs allows them to get
close to a target; however, they are non-targeted. Tumour blood vessels formed through
angiogenesis tend to be irregular and more permeable, allowing for “passive targeting” of
AuNPs due to the enhanced permeability and retention (EPR) effect.13 Therefore, the
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visualization and/or treatment of a desired target may be difficult with AuNPs as they can
accumulate in various locations. For this reason, development of targeted AuNPs would
be advantageous as they could accumulate in higher concentration in the tissue of
interest, which could prove useful for both diagnostic and therapeutic purposes.
Nanoparticles show great potential for cancer targeting, as they are multifunctional. As a
result, they can be used to attach not only a targeting entity to give the probe specificity,
but also have the ability to attach an imaging moiety, allowing for external
visualization;14-17 a druggable target for drug delivery;18, 19 or a radiotherapeutic isotope.20
Therefore, nanoparticles can simultaneously be targeted using a peptide, antibody or
small molecule, while still allowing for imaging or therapy through the attachment of a
radioisotope, fluorescent dye or drug to the same nanoparticle. Targeted AuNPs can also
be used to induce thermal ablation of tumours through irradiation with radio frequency
(RF) radiation due to their inherent thermoablative properties.21
In a study by Morales-Avila et al.,

99m

Tc labelled HYNIC-GGC was attached to gold

nanoparticles, along with c[RGDfK(C)] to image tumour angiogenesis.22 Through in vivo
mouse studies, they found that these nanoparticles showed increased tumour uptake when
compared to

99m

Tc labelled HYNIC-c[RGDyK] which was not attached to the AuNPs.

Therefore, attaching a known targeting peptide to gold nanoparticles can increase tumour
uptake in vivo.
The AuNPs used in this study are spherical and small, approximately 3 nm. 23 Through
PEGylation, these nanoparticles have been made water-soluble, making them suitable for
biological studies. They are soluble not only in water, but also many other organic

120

solvents. These PEGylated AuNPs have been previously functionalized with a maleimide
for use in Michael addition reactions.24-26 They have also been functionalized with an
azide27 or dibenzocyclooctyne (DBCO)28 for use in interfacial strain-promoted azidealkyne cycloaddition (I-SPAAC) reactions. In this study the AuNPs are functionalized
with DBCO at the interface to be used in an I-SPAAC reaction with an azide
functionalized peptide in order to make the AuNPs targeted. This method of
bioconjugation gives the advantage of using a bioorthogonal “click” reaction that can be
performed under copper free conditions, making it more suitable for biological studies
than the copper-catalyzed azide-alkyne cycloaddition.
Targeting of AuNPs can be accomplished using a targeting entity, such as a peptide,
antibody, or small molecule. One such peptide is bombesin, a tetradecapeptide isolated
from the skin of the European fire-bellied toad, Bombina bombina.29 It specifically
targets cell surface gastrin-releasing peptide (GRP) receptors, which are overexpressed in
prostate cancer cells,30-33 and has been shown to target prostate cancer when conjugated
to nanoparticles.34, 35 There are four bombesin receptor subtypes that are known; BB1,
BB2, BB3, and BB4. It was found that a truncated pan-bombesin, [D-Phe6, β-Ala11,
Phe13, Nle14]bombesin-(6-14) (Figure 5.1), successfully targets all four bombesin receptor
subtypes with high affinity and specificity.36-38
Bombesin peptides have been shown to retain high affinity after extensive modifications
to the N-terminus;30, 39-41 therefore, a PEG azide was added to the N-terminus of the panbombesin peptide not only to add the azide functionality, but to also provide distance
between the targeting peptide and the nanoparticle. This allowed for attachment of the
peptide to the DBCO functionalized AuNP through an I-SPAAC reaction. After
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characterization through IR spectroscopy and –potential analysis, these nanoparticles
were then used for in vitro cell studies using a human prostate cancer cell line (PC-3) and
the uptake visualized through transmission electron microscopy (TEM).

Figure 5.1: Structure of natural bombesin, truncated pan-bombesin, [D-Phe6, β-Ala11,
Phe13, Nle14]bombesin-(6-14) and the azide functionalized pan-bombesin peptide 5.1

5.2 Results & Discussion
5.2.1

Peptide Synthesis

A pan-bombesin peptide, [D-Phe6, β-Ala11, Phe13, Nle14]bombesin-(6-14), was
synthesized by standard 9-fluorenylmethoxycarbonyl (Fmoc) solid-phase peptide
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synthesis using rink amide 4-methylbenzhydrylamine (MBHA) resin. A PEG-azide was
added to the N-terminus of the synthesized peptide through standard coupling methods in
order to provide a point of attachment for the peptide to the DBCO functionalized AuNP
through I-SPAAC (Figure 5.1). Once complete, the peptide was removed from the resin
and purified by preparative HPLC-MS to give the desired azide modified pan-bombesin
peptide 5.1.

5.2.2

Model I-SPAAC Reaction

A model I-SPAAC reaction (Scheme 5.1) was performed using the bombesin azide
peptide (5.1) and a PEGylated DBCO in acetonitrile. The reaction was followed by
UHPLC-MS and was complete after 1 hour at room temperature, demonstrating the
suitability of the synthesized peptide for an I-SPAAC reaction with the DBCO
functionalized AuNP.

Scheme 5.1: Model I-SPAAC reaction of DBCO and bombesin azide peptide 5.1
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5.2.3

Functionalization of Gold Nanoparticles

The DBCO functionalized AuNPs were prepared according to previously published
procedures.23, 28 The DBCO-AuNPs were then reacted with the bombesin azide peptide
(5.1) in an I-SPAAC reaction (Scheme 5.2) giving a final yield of approximately 60% of
reacted DBCO. This was slightly lower than the 70% yield seen with the Michael
addition reaction of the maleimide-AuNPs,24 and similar to the 60% yield seen with ISPAAC reaction of the azide-AuNPs.28 This relatively low yield is most likely due to the
steric hindrance from the large size of the peptide and the small gold core diameter.

Scheme 5.2: I-SPAAC reaction between DBCO functionalized AuNPs and bombesin
azide peptide 5.1
The bombesin-AuNPs were characterized through IR spectroscopy and –potential
measurements. The IR spectrum of the bombesin-AuNPs (5.4) compared to that of
bombesin-azide (5.1) and DBCO-AuNPs (5.3) (Figure 5.2) clearly shows the absence of
the azide stretching mode at 2100 cm-1, a marked increase of the N-H stretching at 3300

124

cm-1 and the appearance of a signal at 1624 cm-1 that corresponds to the amide bond
stretch of the peptide which differs from the amide bond stretch of the DBCO-AuNPs,
that instead falls at 1660 cm-1. This indicates that the washing procedure used is effective
in removing the unreacted peptide and that the peptide has been successfully conjugated
to the AuNP surface.

Figure 5.2: IR spectra of a) Bombesin-AuNPs (5.4), b) Bombesin-azide (5.1) and c)
DBCO-AuNPs (5.3)
Finally, the success of the bioconjugation through the I-SPAAC reaction was confirmed
by the change in the AuNPs surface charge. After the bioconjugation of the bombesin the

–potential of the AuNP shifts from -36.1 eV to -59.4 eV confirming the presence of the
peptide on the AuNPs surface and showing an excellent stability of the AuNPbioconjugate in an aqueous solution.
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Toxicity of gold nanoparticles is size-dependent. It has been found that AuNPs between
1-2 nm are toxic, with nanoparticles that are either smaller or larger being non-toxic.42, 43
This is in part due to the fact that 1.4 nm AuNPs can fit into the major groove of DNA
and coordinate irreversibly.44 They also display reticuloendothelial system (RES) uptake,
which causes accumulation in the liver, spleen, bone marrow, and other non-targeted
areas. However, it was found that PEGylation of the nanoparticles can reduce this
accumulation and increase circulation times as the nanoparticles become more
hydrophilic and the surface energy is decreased, resulting in less aggregation of the
nanoparticles.45
This reduction in toxicity through PEGylation also applies to small gold nanoparticles. In
a study by Gu, et al., it was shown through cell viability tests that PEGylated 3.7 nm
AuNPs showed higher than 85% cell viability after incubation with a 10 µM of the
nanoparticles for 24 h, and 70% cell viability after 72 h.46 A previous study was
performed with the same 3 nm AuNPs used in the current study. The AuNPs were
conjugated with a gadolinium(III) chelate for in vivo mouse studies using MRI.24 In the
study, 200 µL of 10 mM Gd3+–AuNPs were injected into the tail vein of a mouse. It was
found that 24 h post-scan, the mouse showed no ill effects. Therefore, these small,
PEGylated AuNPs do not appear to be toxic.

5.2.4

Transmission Electron Microscopy

In vitro cell studies were performed using PC-3 cells, a human prostate cancer cell line
that is androgen independent and highly tumorigenic. This cell line was chosen as it
expresses high levels of GRP receptors,47 which is the desired target for the bombesin
functionalized AuNPs. It has also been shown that there are 44, 000 bombesin receptor
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sites on these cells.48 The cells were incubated with the AuNPs in the following manner.
The first was a targeting study involving cells incubated with a 1 mg/mL solution of
bombesin conjugated AuNPs. A blocking study was also performed with cells that were
incubated with a 50 µg/mL solution of bombesin peptide for 2 hours followed by
incubation with a 1 mg/mL solution of bombesin conjugated AuNPs. Finally, a control
study using cells incubated with a 1 mg/mL solution of AuNPs was performed.
The cells were then embedded in epon-araldite plastic and cut into 70 nm slices using an
Ultracut ultramicrotome. The slices were collected on copper grids and visualized by
transmission electron microscopy (TEM) at 60 kV. This was done with the cells
incubated with the targeted bombesin conjugated AuNPs, the cells blocked with peptide,
and the control cells.
The targeted AuNPs showed considerable uptake, as would be expected given that they
are designed to target the GRP receptors that are overexpressed on the PC-3 cells used.
The pan-bombesin peptide used is a bombesin receptor agonist,49 and once bound to the
GRP receptors found on the surface of the PC-3 cells, the receptor-ligand complex can
undergo internalization.50 As opposed to compounds that remain on the cell surface, this
internalization is ideal as it increases retention in the target tissue.51 This internalization
can be seen in the TEM images of the targeted nanoparticles (Figure 5.3a and b).
The blocking study incubated the cells with bombesin for 2 h before adding the targeted
bombesin-AuNPs. This study showed less uptake of the AuNPs than with the targeted
nanoparticles (Figure 5.3c and d). While there was a reduction in cellular uptake, the
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multi-valent targeting capability of the bombesin-AuNPs may render it difficult to
adequately block the target receptor with mono-valent peptide ligand.
The control cells were incubated with only AuNPs, and thus are not targeted. As would
be expected, these cells showed minimal uptake of the nanoparticles (Figure 5.3e and f).
Figure 5.3 shows TEM images of each study, representative across all cells, where the
AuNPs can be seen as small black dots indicated by the black arrows.

Figure 5.3: TEM images at 60 kV of AuNPs (indicated by black arrows) in PC-3 cells.
A) Cell incubated with targeted AuNPs conjugated with bombesin at a magnification of
19000 and B) 64000; C) blocking study cell at a magnification of 19000 and D) 64000;
E) control cell at a magnification of 19000 and F) 64000
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Grid-based manual counting of the TEM images at a magnification of 64000 (Figure
5.3b, d and f) was performed in order to quantify the nanoparticle uptake. It was
determined that the cells showed a ratio of approximately 2:4:7 nanoparticles for
control:blocking:targeted, indicating that the targeted AuNPs displayed higher uptake
than in either the blocking or control studies.
The AuNPs appeared to be dispersed fairly uniformly throughout the cell, with no
accumulation around any particular organelle. It is also important to note that all studies
showed no AuNPs around the cells; all AuNPs were either in the cells or in the vesicles
surrounding the cells. This demonstrates that the targeted bombesin-AuNPs show
specificity for the receptors present on the prostate cancer cells used, and thus have
potential to be used to target prostate cancer for both diagnostic and therapeutic purposes.
To our knowledge, this is the first example of visualizing in vitro cell uptake of bombesin
conjugated AuNPs via TEM.
Bombesin has been conjugated to AuNPs for prostate cancer imaging in the past. 42, 52-54
However, these previous examples were not PEGylated. This PEGylation not only lowers
toxicity, but also increases the solubility of the AuNPs. Therefore, our bombesin
functionalized AuNPs have solubility of >10 mg/mL in water, whereas the best solubility
reported for bombesin functionalized AuNPs was <3 mg/mL in PBS buffer.53 Solubility
in water is a very important consideration when using nanoparticles for animal studies;
therefore, these new water-soluble bombesin functionalized AuNPs are much more
suitable for in vivo studies due to their increased solubility in water.
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Peptides are most commonly conjugated to AuNP surface through a thiol, usually a
cysteine42 or disulfide,53 or an N-terminal primary amine such as through the ɛ-amine of a
lysine.52, 54 A much more convenient way of functionalizing AuNPs is through the use of
click chemistry, which is inherently quick, easy and reproducible. Our AuNPs are
functionalized with DBCO, allowing for the use of I-SPAAC for conjugation of an azide
modified peptide to the AuNP. Azide modification of peptides is easily accomplished
through the addition of a commercially available PEG-azide. Using strain-promoted click
chemistry has the added advantage of not requiring a copper catalyst to drive the reaction,
further enhancing its compatibility for in vivo studies.

5.3 Conclusions
An azide modified pan-bombesin peptide was successfully synthesized and conjugated to
DBCO functionalized AuNPs, creating targeted, water-soluble AuNPs. These were
formed through I-SPAAC, providing a quick, easy and bioorthogonal method of
conjugation of a peptide to AuNPs. The bioconjugation was confirmed through IR
spectroscopy and –potential measurements, showing that a stable bioconjugate was
formed. Through in vitro TEM studies, it was shown that the targeted AuNPs were
internalized by the PC-3 cells in much higher concentration than either the blocking or
control studies. Bombesin has been shown to target the GRP receptors that are overexpressed on PC-3 cells, and through this study it has been shown that this is still the case
when bombesin is conjugated to small, water-soluble AuNPs. This provides a new
platform for the conjugation of bombesin to AuNPs while also allowing for addition of a
radioisotope, dye or drug through I-SPAAC with free DBCO on the nanoparticles
allowing them to be utilized for targeting prostate cancer for both diagnosis and therapy.
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5.4 Experimental
Materials & Methods
All chemicals were purchased from Sigma-Aldrich, Caledon, Cambridge Isotope
Laboratories, Commercial Alcohols, BDH, Spectra/Por, Novabiochem, Aapptec, Peptides
International, Chem-Impex, Wisent Inc. and Life-technologies and were used without
further purification unless indicated. For HPLC-MS, a Waters, Inc. system was used,
consisting of a Waters 2998 Photodiode Array Detector and a Waters 2767 Sample
Manager. For analytical HPLC-MS studies, a Sunfire RP-C18 4.6 x 250 mm, 5 μm
column was used. For preparative HPLC-MS work, a Sunfire RP-C18 19 x 150 mm, 5
μm column was used. In both cases, absorbance was detected at wavelengths of 220 nm
and 254 nm. A gradient solvent system consisting of CH3CN + 0.1% of TFA (solvent A)
and H2O + 0.1% of TFA (solvent B) was used. For analytical UHPLC-MS studies, a
Waters, Inc. Acquity UPLC H-Class system was used, combined with a Xevo QTof. For
analytical UHPLC-MS studies, a Waters Acquity UPLC BEH C18 2.1 x 50 mm, 1.7 μm
column was used. A gradient solvent system consisting of CH3CN + 0.1% formic acid
(solvent C) and H2O + 0.1% formic acid (solvent D) was used. An INOVA 400 NMR
spectrometer was used for 1H NMR studies. Chemical shifts are reported in parts per
million (ppm) relative to TMS (0.00 ppm). For electro-spray ionization (ESI) mass
spectra a Micromass Quattro Micro API mass spectrometer was used. For cell
centrifugation, an IEC Centra CL2 was used. For TEM, an Ultracut Ultramicrotome was
used for sample preparation, and a Phillips CM10 TEM with Digital Camera Output was
used for imaging. Infrared spectra were recorded using a Bruker Vector33 spectrometer
by making a thin film of sample onto a KBr disk. ζ-potential measurements were
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performed using a Zetasizer Nano-ZS (Malvern Instrument). A solution of AuNPs in PBS
pH 7.0 was prepared with concentration 0.5 mg ml-1. 1 ml of this solution was inserted in
a latex folded capillary cell equipped with electrodes and the ζ-potential was calculated
by employing the Huckel approximation.
Bombesin-azide Peptide (5.1)
The peptide was synthesized on-resin using standard Fmoc solid-phase peptide chemistry
by manual synthesis using Fmoc protected rink amide MBHA resin (0.5 mmol, loading
0.52 mmol/g). The Fmoc protecting group was removed by treatment with 20%
piperidine in N,N-dimethylformamide (DMF) for 5 and 15 minutes, followed by rinses
with dichloromethane (DCM) and DMF. Fmoc protected amino acids were then coupled
from C-terminus to N-terminus for 1 h and 45 min using 3 eq. of Fmoc amino acid, 3 eq.
of 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate
(HCTU) and 6 eq. of N,N-diisopropylethylamine (DIPEA) in 5 mL DMF. Finally, a 550
MW N3-(PEG)7-COOH spacer was coupled overnight using 3 eq of the spacer, 3 eq
HCTU and 6 eq DIPEA in 5 mL DMF. Once complete, the peptide was deprotected and
cleaved from the resin by treatment with trifluoroacetic acid (TFA) containing water
(2.5% v/v) and triisopropylsilane (2.5% v/v) as scavengers for 4 h. Purification was
performed by preparative HPLC-MS (linear gradient of 30-70% solvent A in B). The
purity of the resultant peptide was determined to be >99% by analytical UHPLC (linear
gradient of 5-60% solvent A in B). This resulted in a 6% yield of bombesin peptide 5.1
(50 mg, 0.03 mmol). HRMS (ESI+): m/z calculated for C79H116N18O21, 1653.8641
[M+H]+; observed 1653.8644 [M+H]+.
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Model I-SPAAC reaction (5.2)
PEG-DBCO (3 mg, 0.007 mmol) was dissolved in 250 μL of acetonitrile. Bombesin
peptide 5.1 (12 mg, 0.007 mmol) was also dissolved in 250 μL of acetonitrile and added
to the DBCO solution. To this, another 500 μL of acetonitrile was added. This was stirred
at room temperature and followed by UHPLC (linear gradient of 20-80% solvent A in B).
The reaction was complete after 1 h. MS (ESI+): m/z calculated for C104H145N20O26,
2090.06 [M+H]+, 1045.54 [M+2H]2+; observed 2090.08 [M+H]+, 1045.53 [M+2H]2+.
Triethylene Glycol Monomethyl Ether AuNP (Me-EG3-AuNP)
Me-EG3-AuNP were synthesized according to our previously established procedure.23
Briefly, 19 mg of HAuCl4·3H2O (49 μmol) were dissolved in 7.5 mL of dry MeOH and
1.25 ml of glacial acetic acid. To this mixture 26 mg of triethylene glycol monomethyl
ether thiol (Me-EG3-SH) (146 μmol) were added. The solution was stirred vigorously for
1 hour. Under vigorous stirring 19 mg of NaBH4 (490 μmol) dissolved in 1.25 mL of
nanopure water was added to the reaction mixture drop wise. After the first 3-4 drops the
solution turned dark brown. The reaction was stirred overnight at room temperature and
was then concentrated at rotavapor, 20 mL of brine were added and the nanoparticles
were extracted with toluene. At the end of the process the water phase was colorless. The
Me-EG3-AuNP solution in toluene was transferred into a clean round bottom flask and
the solvent was evaporated leaving a film of AuNPs that was washed with hexanes to
remove the excess of Me-EG3-SH. The nanoparticles were then re-dissolved in nanopure
water and purified by dialysis overnight (MWCO 6000-8000 Da).
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H NMR shows the presence of three broad peaks: one at 3.34 ppm that corresponds to

the –CH3 at the nanoparticle’s interface, and one at 3.58 ppm and one at 3.66 ppm related
to the protons of the ethylene glycol units.
HOOC-EG4-AuNP
HOOC-EG4-AuNPs were synthesized according to our previously established
procedure.28 Briefly, 74 mg of Me-EG3-AuNP were dissolved in 5 mL of DCM in a 25
mL round bottom flask. To this mixture were added 11 mg of HOOC-EG4-SH. The
reaction was allowed to proceed for 30 minutes and the solvent was removed under
vacuum. The AuNP film was washed with hexanes and isopropyl alcohol and then the
HOOC-EG4-AuNP were re-dissolved in milliQ water. The solvent was removed and the
particles were washed and re-dissolved 2 more times. The removal of free thiols was
monitored through 1H NMR spectroscopy by the disappearance of sharp peaks. The 1H
NMR of the clean HOOC-EG4-AuNPs shows the appearance of a small and broad peak at
4.11 ppm that corresponds to the two protons belonging to the carbon alpha of the
carboxylic acid group in the carboxy-terminated ligands. These AuNPs contain the
carboxylic group in concentration 0.46 µmol mg-1.
DBCO-AuNP (5.3)
DBCO-AuNPs were synthesized according to our previously established procedure.28
Briefly, to a 25 mL round bottom flask were added 65 mg HOOC-EG4-AuNPs (30 µmol
of –COOH). The flask was purged with argon for 15 minutes and then 9 mL of dry DMF
were added. After addition of the DMF, 16 μL (90 μmol) of DIPEA was added to the
AuNP solution and the reaction was cooled down to 0°C on an ice bath. In a separate
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flask, 23 mg (60 μmol) of O-Benzotriazole- N,N,N',N'-tetramethyl- uronium-hexafluorophosphate (HBTU) was placed under argon followed by addition of 5 mL of dry DMF.
The HBTU solution was purged for 15 minutes and was then added to the AuNP solution
and allowed to stir for 15 minutes at 0ºC. In another flask, 17 mg (60 μmol) of DBCOamine was placed under argon and dissolved in 3 mL of dry DMF. After 15 minutes of
purging, the DBCO-amine solution was added to the AuNP reaction solution and the ice
bath was removed. The reaction was allowed to proceed overnight under an inert
atmosphere. The next day the reaction mixture was inserted into a dialysis bag (MWCO
6000-8000 Da) and dialyzed against DMF to remove the reaction byproducts. The DMF
was changed every 2 hours twice. Finally the sample was dialyzed against water
overnight. As previously reported, the DBCO-AuNPs prepared following this procedure
were found to contain the DBCO in concentration 0.1 µmol mg-1.
Bombesin-AuNP (5.4)
In a typical bioconjugation procedure 20 mg of DBCO-AuNP 5.3 (2 µmol of DBCO)
were mixed with 10 mg of bombesin-azide 5.1 (6 µmol) in 5 mL of dry methanol. The
reaction was allowed to proceed for 2 hours. After 2 hours the methanol was evaporated
and bombesin-AuNP and excess bombesin-azide were re-dissolved in 4 mL of a 1:1
mixture MeOH/H2O. The excess peptide was then removed by centrifugation (6000 rpm
for 7.5 min) using Millipore centrifuge filters (MWCO 10000 Da). Bombesin-AuNP
were never allowed to dry completely on the filter taking care that 500 µL of solvent was
still present inside the filter after centrifugation. Bombesin-AuNP were washed 4 times
and finally transferred into a vial. The solvent was completely evaporated, and the
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bombesin-AuNPs were re-dissolved in MilliQ water to obtain a final concentration of 10
mg/mL. This solution was stored at 4ºC.
In order to calculate the I-SPAAC reaction yield, the purification washes were then
collected and the solvent was evaporated carefully. This resulted in 4.7 µmol of
bombesin-azide being recovered, indicating that ~60% of the interfacial DBCO reacted
with the peptide.
Cell Preparation
PC-3 cells were grown in T-75 flasks using Ham’s F-12 media supplemented with 10%
fetal bovine serum and were incubated with a 1 mg/mL solution of gold nanoparticles
either with or without bombesin to a final concentration of 50 μg/mL, at 37o C for 24
hours. For blocking studies, bombesin was added to the cells to a final concentration of
50 μg/mL for 2 hours, before the addition of the bombesin-containing nanoparticles.
After 24 hours, the cells were gently washed with phosphate buffer saline (PBS), gently
lifted using a 0.05% Trypsin-EDTA solution and centrifuged at 1200 rpm for 5 minutes.
The cell pellet was washed two times with PBS and fixed with a 2% glutaraldehyde in
PBS solution overnight. Cells were then washed 3 times with PBS to remove the fixing
agent, re-suspended in PBS and analyzed by transmission electron microscopy (TEM).
Transmission Electron Microscopy
Once the cells were fixed with a 2% gluteraldehyde in PBS solution, they were washed
three times with PBS buffer and re-suspended in 2% OsO4 for 1 h. They were then
washed three times with double distilled water. Cells were set in a 1% agarose solution

136

that was then cut into small cubes and subjected to dehydration in acetone series; percent
acetone in water: 20%, 50%, 70%, 90%, 95%, 100%, 100%, 100%. The cells were then
embedded with a series of epon-araldite plastic in acetone; 50%, 66%, 100%, 100%. The
samples were then set in a form using epon-araldite plastic. The moulds were then cut
into 70 nm slices using an Ultracut ultramicrotome. The slices were collected on copper
grids and visualized using a Phillips CM10 TEM at 60 kV.
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Chapter 6

6

Conclusions

Molecular imaging has become a true multi-disciplinary approach for the non-invasive
diagnosis of diseases; with biologists discovering biological targets, chemists developing
imaging probes specific for the desired target, and physicists and engineers designing the
instrumentation needed to image the probe accumulation in the body.1 With contributions
from so many fields, molecular imaging has quickly become an indispensable tool since
its formalization only a few decades ago. As such, many critical advancements have been
made in recent years, resulting in an increase in the number of PET and SPECT facilities
for both clinical and research applications.2 However, there is still a need to improve the
current generation of radiopharmaceuticals. In order to meet this need, new approaches to
radiopharmaceutical development are required. This includes improved design, synthesis
and methods of incorporating radionuclides that are both quick and efficient with the
hopes of creating radiopharmaceuticals that have increased in vivo stability and improved
target affinities, resulting in increased target-to-background ratios and higher quality
images.3
In designing pharmaceuticals, the issue of isomer formation is a major concern as each
isomer formed can possess unique properties. This is also of concern when synthesizing
imaging agents. In previous work in our lab with cyclic RGD peptides containing an N αsubstituted histidine chelator, it was discovered that isomers were formed as a result of
rhenium(I) tricarbonyl coordination. This isomer formation was investigated through the
synthesis and characterization of three small molecule and one peptide-like model
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histidine chelators. The first small molecule consisted of a benzylated histidine that
contained a secondary alpha amine as a model system. The second was a protected
version of the first where the imidazole-N3 was protected to ensure histidine linkage
isomers were not being observed. The third was a methylated version of the first making
the alpha amine tertiary. The final model was a dipeptide to compare isomer formation
between small molecules and peptides. Through 1H and various 2D NMR spectroscopic
techniques, it was determined that the isomers formed by the coordination of rhenium
with histidine were diastereomers of the secondary alpha amine on the bifunctional
histidine chelator and the structures of both the major and minor isomers for the model
chelators were determined.
Isomers can be very problematic in radiopharmaceutical synthesis as they can lead to
side-effects, toxicity and can possess different pharmacokinetic properties. Histidine is a
very effective chelator for rhenium and technetium-99m tricarbonyl; as such, this study
shows that awareness of isomer formation is critical for development of any
radiopharmaceuticals containing this chelation system or a similar chelation system with
a coordinating secondary amine.
Histidine can also function as a mono- or bidentate chelator for various metals, and has
been found to be effective in stabilizing small peptide turns through this coordination. 4-6
A pentapeptide of the sequence Ac-HAAAH-OH was designed such that the terminal
histidines would be able to coordinate [99Tc/Re(CO)3]+ in a [2+1] fashion using the
imidazole of the N-terminal histidine and the imidazole and carboxylic acid of the Cterminal histidine. This coordination would effectively cyclize the peptide, forming an
integrated radiolabelled peptidomimetic. Through 1H and 2D NMR spectroscopy of the
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coordinated peptide it was determined that coordination of the metal was occurring in a
[2+1] manner, and thus cyclizing the peptide in the process. The C-terminal histidine is
functioning as a bidentate chelator and preferentially coordinates the metal through the
imidazole-N1, as was seen in Chapter 2. However, the N-terminal histidine is a
monodentate chelator with the potential to coordinate through either the imidazole-N1 or
N3, leading to eight possible isomers of the cyclized coordinated peptide. Through the
combination of 2D and VT NMR spectroscopy along with computational studies, the
most probable structure of the cyclic peptide was determined.
This technique could be applied to the development of various biologically relevant
cyclic peptides, such as RGD, to form integrated radiopharmaceuticals that become
biologically active only upon incorporation of the metal. This technique can also be used
to synthesize focused libraries of technetium-99m labelled cyclic pentapeptides in order
to explore the surrounding chemical space.7 Development of these integrated molecular
imaging probes that are biologically active only when cyclized with a metal hold much
promise for the future of technetium-99m based radiopharmaceuticals as they allow for
increased specificity of the probe for the target of interest, increased binding affinities,
increased bioavailability and decreased receptor promiscuity.
Cyclic peptidomimetics were also developed which incorporated both an azide and
alkyne functionality such that triazole formation through a click reaction would form not
only a cyclic peptide, but would also result in a chelation site for rhenium/technetium99m tricarbonyl. This follows an integrated design as the chelator, and thus the metal, is
incorporated into the backbone of the cyclic peptide. Synthesis of this "click to cyclize
and chelate" model was attempted through three different clickable peptide systems. The
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first two systems contained an azide modified amino acid at the C-terminus of the
peptide, and different alkyne modified amino acids at the N-terminus. It was
demonstrated that both of these chelators were able to coordinate [Re(CO)3]+ through the
synthesis and characterization of model chelation systems. The third system had inverted
functionality with a lysine, modified at the alpha amine with an alkyne, placed at the Cterminus. The peptide could then be extended from the side-chain amine of the lysine and
an azide attached to the N-terminus. Once clicked, all the proposed systems had the
potential to form a cyclic peptide and in the process, a chelator for rhenium/technetium99m tricarbonyl. However, all attempts at synthesizing and characterizing these systems
were unsuccessful.
Although the idea of click to cyclize and chelate was unsuccessful, click chemistry still
has great potential for applications in radiopharmaceutical development due to its broad
scope;8 especially in terms of click-to-chelate for labelling biomolecules with
techenetium-99m.9 This click-to-chelate approach can also be used to coordinate
therapeutic isotopes of rhenium (186 and 188). This permits both diagnostic, when
technetium-99m is coordinated, and therapeutic, by substituting for rhenium-186/188,
applications with the same probe. Synthesis of imaging probes with different
radionuclides for different imaging modalities from a single precursor using click
reactions, allows for the comparison of different imaging probes and modalities.10 The
development

of

multifunctional

radiopharmaceuticals

with

click

chemistry11

demonstrates the potential use in theranostics, which combines therapeutic and diagnostic
entities on the same probe, in the same dose. Click chemistry would allow both a
diagnostic and a therapeutic entity to be “clicked” to a functionalized targeted probe
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allowing for detection of probe localization while at the same time, providing the patient
with a therapeutic dose.
A promising pathway for the development of theranostic probes is through the use of
gold nanoparticles.12 Their multifunctionality allows for the addition of a targeting entity
while at the same time containing a diagnostic radionuclide, a therapeutic radioisotope, or
both simultaneously. One method to attach different entities to these nanoparticles is with
click chemistry as was described in Chapter 5. In this chapter, small, water-soluble gold
nanoparticles were functionalized with a pan-bombesin ligand that has been shown to
target gastrin-releasing peptide receptors that are overexpressed on prostate cancer (PC-3)
cells. Bioconjugation was achieved with copper-free click chemistry to react an azide
modified pan-bombesin with DBCO functionalized gold nanoparticles. These targeted
AuNPs were incubated with PC-3 cells and the uptake visualized by TEM studies.
Blocking studies where the AuNPs were first incubated with bombesin, as well as control
studies where the cells were incubated only with AuNPs, were also performed and
visualized by TEM. These images showed specific accumulation of the targeted
nanoparticles in the PC-3 cells, demonstrating their potential for both diagnostic and
therapeutic purposes.
Traditionally, conjugation of biomolecules with gold nanoparticles uses thiol-Au
chemistry, which is sensitive to reducing conditions. Click-based bioconjugates have a
much broader scope as they form a much more stable bioconjugate, thus expanding their
potential applications.12 This system holds the potential for attachment of other azide
modified entities through click chemistry as the AuNPs are functionalized with DBCO.
This would allow for attachment of multiple entities to the nanoparticles either
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individually or simultaneously. If both a diagnostic label, such as technetium-99m or
fluorine-18, is attached along with a therapeutic isotope, such as rhenium-186/188 or
iodine-131, simultaneous imaging and therapy can be accomplished with the theranostic
agent all in one dose.
In conclusion, this thesis has developed several novel methods for the synthesis of
molecular imaging agents. Molecular imaging and radiopharmaceutical development are
essential and emerging fields. Advancement in identification, synthesis, and
characterization of novel molecular imaging agents is critical for the creation of superior
radiopharmaceuticals capable of producing higher resolution images allowing for earlier
detection of disease on-set and better methods of tracking disease progression and
treatment. Integrated technetium-99m based radiopharmaceuticals will aid in creating
targeted imaging agents with low molecular weight and improved affinity due to the
conformational constraint induced by metal incorporation.13 Gold nanoparticles offer
additional multifunctionality as a distinct advantage over traditional methods of
developing pharmaceuticals, with the ability to conjugate numerous diagnostic and
therapeutically relevant entities on the same probe.14 The use of click chemistry in
radiopharmaceutical design is still an emerging field, and as a result, there have been very
few examples of marketed pharmaceuticals containing a 1,2,3-triazole. As such, an
emergence of triazole containing imaging agents and therapeutics should be expected in
the coming decades.15, 16
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Appendix A : Characterization of Select Compounds
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Figure A1: 1H NMR (400 MHz, MeOH-d4) of 2.6

ES-2-99-QC3-0to40-15min
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Figure A2: Analytical HPLC trace, UV absorbance detected from 210-800 nm (RP-C18
4.6 x 250 mm, 5 μm), of 2.6
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Rhenium(I) tricarbonyl-Nα-benzyl-L-histidine (2.1)
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Figure A3: 1H NMR (400 MHz, MeOH-d4) of 2.1

ES-1-143-NMR-25to60-20min

2: Diode Array
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Figure A4: Analytical HPLC trace, UV absorbance detected from 210-800 nm (RP-C18
4.6 x 250 mm, 5 μm), of 2.1
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Figure A5: gCOSY spectrum (400 MHz, MeOH-d4) of 2.1
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Nα-benzyl-L-histidine(Trt)-OMe (2.8)
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Rhenium(I) tricarbonyl-Nα-benzyl-L-histidine(Trt) (2.2)
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Figure A7: 1H NMR (400 MHz, CDCl3) of 2.2

ES-2-117-sol-30to95-20min
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Figure A8: Analytical HPLC trace, UV absorbance detected from 210-800 nm (RP-C18
4.6 x 250 mm, 5 μm), of 2.2
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Figure A9: 1H NMR (400 MHz, MeOH-d4) of 2.10

ES-2-127-deprot-TFA-5to40-15min-sunfire-3
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Figure A10: Analytical HPLC trace, UV absorbance detected from 210-800 nm (RP-C18
4.6 x 250 mm, 5 μm), of 2.10
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Rhenium(I) tricarbonyl-Nα-benzyl(methyl)-L-histidine (2.3)
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Figure A11: 1H NMR (400 MHz, MeOH-d4) of 2.3

ES-2-107-QC1-35to60-15min
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Figure A12: Analytical HPLC trace, UV absorbance detected from 210-800 nm (RP-C18
4.6 x 250 mm, 5 μm), of 2.3
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Figure A13: gCOSY spectrum (400 MHz, MeOH-d4) of 2.3
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Figure A14: NOESY spectrum (400 MHz, MeOH-d4) of 2.3
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N-iodocarbonyl-O-methyl phenylalanine (2.11)
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Figure A15: 1H NMR (400 MHz, MeOH-d4) of 2.11

ES-2-83-NaI-3-20to80
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Figure A16: Analytical HPLC trace, UV absorbance detected from 210-800 nm (RP-C18
4.6 x 250 mm, 5 μm), of 2.11
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Nα-histidinyl-acetyl-phenylalanine (2.12)
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Figure A17: 1H NMR (400 MHz, MeOH-d4) of 2.12

ES-2-93-deprot-0to40-QC3
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Figure A18: Analytical HPLC trace, UV absorbance detected from 210-800 nm (RP-C18
4.6 x 250 mm, 5 μm), of 2.12
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Rhenium(I) tricarbonyl-Nα-histidinyl-acetyl-phenylalanine (2.4)
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Figure A19: 1H NMR (600 MHz, DMF-d7) of 2.4
ES-2-121-coordsol-25to60-15min
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Figure A20: Analytical HPLC trace, UV absorbance detected from 210-800 nm (RP-C18
4.6 x 250 mm, 5 μm), of 2.4
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Figure A21: gCOSY spectrum (600 MHz, DMF-d7) of 2.4
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Figure A23: 13C NMR (100 MHz, CDCl3) of 3.1
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Figure A25: 13C NMR (100 MHz, CDCl3) of 3.2
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Figure A26: 1H NMR (600 MHz, CDCl3) of 3.3
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Figure A27: 1H NMR (400 MHz, CDCl3) of 3.4
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Figure A28: 13C NMR (100 MHz, CDCl3) of 3.4
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Rhenium(I) tricarbonyl-1-(benzyl)triazole-pyridine-2-methylamino-acetate (3.5)
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Figure A29: 1H NMR (600 MHz, CDCl3) of 3.5
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Fmoc-Lys(N3)-OH (3.6)
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Figure A30: 1H NMR (400 MHz, CDCl3) of 3.6
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Figure A31: 1H NMR (400 MHz, CDCl3) of 3.11
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N-propargyliminodiacetic acid (3.12)
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Figure A32: 1H NMR (400 MHz, D2O) of 3.12
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Figure A33: 1H NMR (400 MHz, CDCl3) of 3.13
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1-(benzyl)triazole-propargyliminodiacetic acid (3.14)
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Figure A34: 1H NMR (400 MHz, MeOH-d4) of 3.14
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Rhenium(I) tricarbonyl-1-(benzyl)triazole-propargyliminodiacetic acid (3.15)
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Figure A35: 1H NMR (400 MHz, MeOH-d4) of 3.15
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Figure A36: 1H NMR (600 MHz, DMSO-d6) of 4.1
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Figure A37: gCOSY spectrum (600 MHz, DMSO-d6) of 4.1
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Figure A38: TOCSY spectrum (600 MHz, DMSO-d6) of 4.1
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Figure A39: 1H NMR (600 MHz, DMSO-d6) of 4.2
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Figure A40: gCOSY spectrum (600 MHz, DMSO-d6) of 4.2
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Figure A41: TOCSY spectrum (600 MHz, DMSO-d6) of 4.2
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Figure A42: 3D structures showing intramolecular hydrogen bonding interactions
(dashed red lines) of the four isomers of the proposed structure of cyclized peptide 4.2
where the imidazole-N1 of the N-terminal histidine is coordinated to the rhenium, with
4.2a having the lowest energy
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Figure A43: 3D structures showing intramolecular hydrogen bonding interactions
(dashed red lines) of the four isomers of the proposed structure of cyclized peptide 4.2
where the imidazole-N3 of the N-terminal histidine is coordinated to the rhenium, with
4.2e having the lowest energy and the same hydrogen bonding interactions as was see in
the VT NMR
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